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SUMMARY 
 
Introduction:  The ability of different polyunsaturated fatty acids (PUFAs), 
especially n-3 PUFAs, to prevent the development of cancer has been under 
intense investigation the past three decades.  Numerous studies have shown 
that these fatty acids can kill cancer cells in vitro as well as in vivo whilst normal 
cells remain unaffected.  Unfortunately, the cellular and molecular mechanisms 
responsible for this phenomenon are still poorly understood.  This study 
investigated the signalling pathways modulated by docosahexaenoic acid 
(DHA) in an adenocarcinoma cell line, in order to shed some light on these 
unknown mechanisms. 
 
Materials & Methods:  NCM460 (normal colon epithelial) and CaCo2 (colon 
adenocarcinoma) cells were cultured and treated with low doses of palmitic acid 
(PMA), oleic acid (OA), arachidonic acid (AA), and DHA.  The effects of these 
fatty acids on the proliferation of the cells were measured with the MTT assay.  
The composition of membrane phospholipids of CaCo2 cells was determined 
after 48h supplementation with different fatty acids by gas chromatography.  
Also, CaCo2 cells were treated with DHA (10 µM) only and proteins were 
harvested at fixed time points ranging from 2 minutes to 48 hours.  The protein 
inhibitors wortmannin (PI3 kinase inhibitor), PD 98059 (MEK inhibitor) and SB 
203580 (p38 inhibitor) and also RNA interference (RNAi) of the p38 MAPK 
protein were used to investigate cross-talk between signalling pathways.  ERK, 
p38 MAP kinase, Akt, and p53 were then analysed by Western blotting using 
phospho-specific and total antibodies.  The cleavage of the apoptotic proteins, 
caspase-3 and PARP were also analysed.  
 
Results and discussion:  MTT assays revealed that none of the fatty acids were 
toxic to normal cells.  In addition, DHA was shown to be most effective to kill 
CaCo2 cells whilst protecting NCM460 cells and a subsequent dose response 
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experiment revealed that lower concentrations are most suitable for this 
purpose.  DHA was also shown to be readily incorporated into phospholipids, 
along with AA.  This is associated with increased membrane fluidity, which 
could affect the localisation, and downstream effects, of various signalling 
proteins within the membrane. Western blot analysis revealed a rapid increase 
in activity in most proteins under investigation, especially ERK and Akt 
(Ser473).  Long-term DHA supplementation suppressed the full activation of 
Akt.  This down regulation of survival signalling could lead to cell death in 
CaCo2 cells.  In addition, it was shown that after 48h, DHA induced the 
cleavage of caspase-3 and PARP, which is indicative of apoptosis.  RNAi 
experiments suggested a possible role for p38 MAPK in the phosphorylation of 
p53 at Ser15, a site which is associated with DNA damage.   
  
Conclusion:  DHA exerts its effects by means of cellular signal transduction 
pathways, particularly by suppression of the important survival-related kinase, 
Akt.  This could have implications for future therapeutic interventions in cancer 
patients, as fatty acids are safe to use and do not interfere with the functionality 
of normal tissue. 
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OPSOMMING 
 
Inleiding:  Die vermoë van verskillende poli-onversadigde vetsure (POVSe), 
veral n-3 POVSe, om die ontstaan van kanker te voorkom, is intens nagevors 
die afgelope drie dekades.  Menigte studies het aangevoer dat hierdie vetsure 
kankerselle in vitro asook in vivo kan doodmaak, terwyl normale selle nie 
daardeur beïnvloed word nie.  Ongelukkig word die sellulêre and molekulêre 
meganismes onderliggend tot hierdie verskynsel nie goed begryp nie.  Hierdie 
studie het verskeie seintransduksie-paaie wat deur dokosaheksaenoësuur 
(DHS) in ‘n adenokarsinoom sellyn gemoduleer word, ondersoek. 
 
Materiale & Metodes:  NCM460 (normale kolonepiteel) en CaCo2 (kolon 
adenokarsinoom) selle is onderhou in ‘n selkultuur-laboratorium en behandel 
met lae dosisse palmitiensuur (PMS), oleïensuur (OS), aragidoonsuur (AS), en 
DHS.  Die invloed van hierdie vetsure op die proliferasie van die selle is d.m.v. 
die MTT toets bepaal.  The samestelling van membraan-fosfolipiede van CaCo2 
selle is na 48h behandeling met die verskillende vetsure bepaal deur middel 
van gaschromatografie.  Die CaCo2 selle is ook met DHA (10 μM) alleenlik 
behandel en teen vaste tydpunte wat wissel van 2 minute tot 48h, waarna 
proteïene geëkstraeer is.  Die proteïen-inhibitore wortmannin (PI3 kinase 
inhibitor), PD 98059 (MEK inhibitor), en SB 203580 (p38 inhibitor) asook RNA-
interferensie (RNAi) teen die p38 MAPK proteïen is ingespan om oorvleueling 
tussen seintransduksie–weë te ondersoek.  ERK, p38 MAPK, Akt, en p53 is 
geanaliseer deur middel van die Western–klad metode met fosfo–spesifieke en 
totale antiliggame.  Die kliewing van die apoptotiese proteïene caspase-3 en 
PARP is ook bepaal. 
 
Resultate en bespreking:  MTT toetse het ontul dat geen vetsure toksies was vir 
die normale selle nie.  Daar is ook gevind dat DHS die mees effektiewe vetsuur 
was om CaCo2 selle te dood, terwyl NCM460 selle beskerm word.  Gevolglik 
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het ‘n dosis-respons eksperiment getoon dat laer konsentrasies die beste 
geskik is vir hierdie doel.  Daar is ook gevind dat DHA maklik in fosfolipiede 
geïnkorporeer word, tesame met AS.  Dit word geassosieer met verhoogde 
membraan-vloeibaarheid, wat die ligging, en ook stroom-af werking, van 
verskeie seintransduksie proteïene in die membraan, kan beïnvloed.  Western-
klad analises het ‘n vinnige verhoging in die aktiwiteite van die meeste 
proteïene onder die soeklig, getoon, veral ERK en Akt (Ser473).  Langdurige 
DHS behandeling het die maksimale aktiwiteit van Akt onderdruk.  Hierdie 
afname van oorlewing-gerigte seine kan lei tot seldood in CaCo2 selle.  Daar is 
boonop geving dat DHS die kliewing van caspase-3 en PARP geïnduseer het 
na 48, wat dui op apoptose.  Uit die RNAi eksperiment kon daar ook ‘n 
moontlike rol vir p38 MAPK in die fosforilering van p53 by Ser15, wat 
geassosieer word met DNS-skade, getoon word. 
 
Gevolgtrekking:  DHS beoefen sy effekte deur middel van seintransduksie 
paaie, veral deur die oorlewing-geassosieerde kinase, Akt, te onderdruk.  Dit 
kan implikasies hê vir toekomende terapeutiese ingrypings in kankerpasiënte, 
aangesien vetsure veilig is om te gebruik en nie skadelik is vir normale weefsel 
nie. 
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CHAPTER 1 
INTRODUCTION AND OBJECTIVES 
 
In recent years, numerous publications have reviewed the area of dietary fatty 
acids and cancer.  The immense interest in this field stems from early 
epidemiological studies on the relation between the intake of fish and marine 
fatty acids and the risks of various cancers.  Also, it is known that at least one 
third of human cancers may be associated with diet, and lifestyle (Bartsch et al., 
1999).  The concept of a dietary intervention to decrease one’s risk of 
developing certain cancers thus seems reasonable, and the notion that certain 
fatty acids have anti-tumourigenic properties, is now widely accepted. 
 
Researchers mostly agree that a high dietary intake of n-6 polyunsaturated fatty 
acids (PUFAs) could lead to increased risks for cancers of the breast, colon, 
and prostate.  On the other hand, the n-3 PUFAs can inhibit the growth of 
tumours, and it is this class of fatty acids that has received the most attention.  It 
is now believed that the balance between the intakes of n-6 and n-3 fatty acids 
are the key to an increased or decreased cancer risk (Kang, 2005).   
 
Although there are numerous studies on this topic, ranging from epidemiological 
studies, studies involving experimental animals as well as those done in cell 
cultures, the mechanisms are poorly characterised.  It is known that fatty acids 
do not harm normal cells (Begin et al., 1985), and this should make fatty acids 
an attractive adjuvant, or perhaps even a replacement, for conventional cancer 
therapies.  Sadly, fatty acids have not received much attention in the clinic, and 
it is hoped that insights into their molecular actions in cancer cells could change 
this. 
 
Therefore, the main objective of the present study was to shed some light on 
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the mechanisms of n-3 PUFAs, particularly docosahexaenoic acid (DHA).   
 
The aims of the current study were threefold: 
1. To test the effects of different fatty acids on the proliferation of both normal 
and cancer cells 
2. To assess the effects of the different fatty acids on the membrane 
phospholipid composition of cancer cells 
3. To investigate the modulation of different signalling molecules by fatty acids 
in cancer cells in an attempt to uncover a possible signalling-dependent 
mechanism. 
 
 3
CHAPTER 2 
LITERATURE REVIEW 
2.1.  CANCER 
2.1.1.  Introduction 
According to the World Cancer Report, a 351-page study released in 2003, 
cancer rates could increase by 50% to 15 million new cases by 2020 (World 
Cancer Report, 2003).  The International Agency for Research on Cancer 
(IARC), a branch of the World Health Organization (WHO) conducted the study 
described in the report. 
 
In 2000, 12% of the 56 million deaths worldwide were due to cancer and more 
than 22 million people were treated for cancer worldwide.  In many countries, 
especially industrialized nations, more than 25% of deaths were attributable to 
cancer, a rate more than twice as high as developing countries in 2000 (Laurier, 
2003).  However, according to the report cancer is now also a major health 
problem in developing nations, matching its effect in industrialized nations for 
the first time.  Industrialized countries with the highest overall cancer rates are:  
the United States of America, Italy, Australia, Germany, the Netherlands, 
Canada and France (Laurier, 2003). 
 
According to the report the most common cancers worldwide are lung, breast 
and colorectal cancer.  Table 1 shows the incidences of cancer worldwide, as 
was reported in 2003. 
 
 4
Table 2.1 Most common cancers worldwide, according to the World Cancer 
Report  (World Cancer Report, 2003). 
Cancer site New cases annually 
Lung 1,2 million 
Breast 1 million 
Colorectal 940 000 
Stomach 870 000 
Liver 560 000 
Cervical 470 000 
Oesophageal 410 000 
Head and neck 390 000 
Bladder 330 000 
Malignant non-Hodgkin’s lymphomas 290 000 
Leukaemia 250 000 
Prostate and testicle 250 000 
Pancreas 216 000 
Ovarian 190 000 
Kidney 190 000 
Endometrium 188 000 
Nervous system 175 000 
Melanoma 133 000 
Thyroid 123 000 
Pharynx 65 000 
Hodgkin’s disease 62 000 
 
2.1.2.  Biology of cancer 
2.1.2.1.  Introduction 
Cancer can be described as a disorder of the balance between cell proliferation 
and cell death.  During the progression of cancer, the tumour cells acquire a 
variety of phenotypic properties that allow them to proliferate both swiftly and 
 5
uncontrollably and spread from their original site to other locations in the body, 
often leading to the death of cancer patients (Hanahan and Weinberg, 2000).   
 
2.1.2.2.  Nomenclature of tumours 
The tissue and cell type from which cancer has arisen, and whether it is benign 
or malignant, determines its classification.  Malignant tumours arising from 
epithelium are termed carcinomas, whereas benign tumours arising from 
epithelium are known as papillomas or adenomas, depending on the tissue type 
or appearance of the tumour (Franks, 1997).  For example, an adenoma has a 
glandular organization.  The corresponding type of malignant tumour is known 
as an adenocarcinoma, implicating a similar glandular structure (Alberts et al., 
2002).  Malignant tumours originating in muscle or connective tissue are known 
as sarcomas.  The various leukaemias are derived from haemopoietic cells.  In 
the nervous system, malignant tumours from neurons are termed blastomas; 
those derived from supporting cells such as astrocytes or oligodendrocytes are 
called cytomas.  Each of the broad categories has various subdivisions, usually 
depending on cell type.  For example, a cytoma of oligodendrocytes is called 
oligodendrocytoma.  Very seldom, tumours that contain a mixture of different 
tissues may be found.  Such tumours of mixed tissues are known as teratomas 
(Franks, 1997).  Approximately 90% of human cancers are carcinomas, 
perhaps because epithelium is the most proliferative tissue in the body or 
because epithelial tissues are most frequently exposed to physical damage and 
harmful chemical agents (Alberts et al., 2002).   
2.1.2.3.  Genetics and carcinogenesis 
Cancer is considered to be a genetic disorder at the somatic cell level, due to 
the apparent link between carcinogenesis (the genesis of cancer) and 
mutagenesis (the production of a mutation in DNA).  In the human body which is 
comprised of more than 1014 cells, billions of cells experience mutations each 
day.  Mutations associated with cancer can involve small-scale changes, such 
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as a point mutation (the substitution of a single nucleotide), or large scale 
abnormalities, including rearrangement of chromosomes, gain or loss of 
chromosomes, or even the integration of viral DNA or RNA (Hanahan and 
Weinberg, 2000; Klug and Cummings, 2003).  Large-scale genomic alterations 
are a common feature of cancer and most tumours are characterized by visible 
changes in chromosomal structure.  Certain chromosomal abnormalities are so 
characteristic that they are used to diagnose a particular type of cancer and 
make predictions about the severity and progression of the disease, such as the 
classical example of the Philadelphia chromosome, an unusually small 
chromosome, observed in chronic myeloid leukaemia (CML) (Wasan and 
Bodmer, 1997; Klug and Cummings, 2003).   
 
It is estimated that at least 50% of all cancers are environmentally induced 
(Klug and Cummings, 2003).  Environmental agents known to increase the 
likelihood of tumour formation are known as carcinogens (or cancer-causing 
agents) and include chemical carcinogens (for example tobacco and asbestos), 
radiation (such as X-rays and ultraviolet light exposure), and viruses (for 
example Helicobacter pylori and human papilloma virus (HPV), that are known 
to induce stomach and cervical cancer, respectively) (Alberts et al., 2002; World 
Cancer Report, 2003).  For cancers that have a discernible external cause, the 
disease does not usually become apparent until long after exposure to the 
causal carcinogen.  The occurrence of lung cancer, for example, only starts to 
increase steeply after 10 to 20 years of heavy smoking (Alberts et al., 2002).  
The majority of carcinogens are also mutagens.   
 
Carcinogenesis is not an immediate event, because a single mutant cell that 
does not proliferate abnormally does no significant damage to its surrounding 
microenvironment, no matter what other confounding properties it may have 
acquired.  Instead, carcinogenesis is a multi-step process, involving a series of 
successive genetic alterations following the initial exposure to the carcinogen.  
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The primary step in carcinogenesis is initiation, which involves DNA damage or 
genomic changes of some sort.  Although cells do possess mechanisms to 
repair damaged DNA, repair cannot be done if cells are in the process of 
replicating DNA while the mutation is induced, and thus the mutation is left 
intact in the replicated DNA (Tennant et al., 1997).  Following initiation, tumour 
promotion by promoting agents is necessary for the development of a tumour, 
because initiated cells remain latent until acted on by promoting agents (Franks, 
1997).  Promoting agents (for example inflammation) are not inherently 
carcinogenic, but they do induce cell division in initiated cells.  It has been 
suggested that promoting agents may interfere with the process of 
differentiation that normally takes place when cells move from the dividing 
population into a population of functioning, usually post-mitotic, cells (Franks, 
1997).  Once such a cell proliferates uncontrollably, it will give rise to a tumour, 
or neoplasm – a relentlessly growing mass of mutant cells.  This is the third 
step:  tumour progression.  Cancer is thus caused by genetic defects within 
somatic cells, enabling them to prosper at the expense of their neighbouring 
cells and ultimately destroy the organism.   
 
As long as the neoplastic cells remain clustered together in a single group, the 
tumour is said to be benign.  Benign tumours usually resemble their tissue of 
origin and may still function indistinguishably from their normal counterparts.  
For example, benign skin tumour cells are likely to continue the production of 
skin pigments.  Benign tumours are usually separated from the neighbouring 
normal tissue by a connective tissue capsule and do not invade its surroundings 
(Franks, 1997).  During this stage, a complete cure is usually attainable by 
surgical removal of the tumour.  However, once such a tumour features more 
severe cellular abnormalities and becomes invasive, it is considered to be 
malignant and the patient is only then said to have cancer.  Such invasiveness 
implies that the tumour cells break away from the primary tumour and enter the 
bloodstream or lymphatic system to form secondary tumours elsewhere in the 
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body, a process known as metastasis  (Alberts et al., 2002).  Malignant tumours 
are not encapsulated like benign tumours.  The standard cellular criteria for the 
diagnosis of a malignant tumour include a local increase in cell number, loss of 
the normal regular arrangement of cells, variation in cell shape and size, an 
increase in nuclear size and total DNA content, increased cell division, and 
abnormal chromosomes (Franks, 1997).  By the time it is detected, a typical 
tumour usually contains about a billion cells or more, often including normal 
cells such as fibroblasts in the supporting tissue (Alberts et al., 2002).   
 
Genes such as fos, raf, ras, and myc that promote cell division under normal 
circumstances are known as protooncogenes.  Because malignant cells have 
acquired the ability to divide seemingly limitlessly, mutations in these 
protooncogenes are often implicated, resulting in their permanent activation.  
The mutant form of a protooncogene is known as an oncogene.  Oncogenic 
DNA viruses (such as the adenoviruses and Epstein-Barr virus) as well as a 
number of retroviruses (i.e. viruses with RNA genomes such as hepatitis C 
virus) also act by inserting viral oncogenes into the host genome, which can 
lead to the transformation of somatic cells, resulting in neoplasms. Those genes 
that normally function to suppress cell division such as p53 and retinoblastoma 
(Rb) are known as tumour suppressor genes and are also often mutated in 
cancer, rendering them inactive (Nigro et al., 1989; Teich, 1997; Klug and 
Cummings, 2003).  A single mutation in an oncogene is usually sufficient to 
induce cancer, whereas two mutations in a tumour suppressor gene are 
generally  required (the so-called “two-hit” model of tumourigenesis) (Knudson, 
1971; Teich, 1997).  According to this model, tumour suppressor genes become 
tumourigenic only once both alleles have been inactivated by separate 
mutations or chromosomal deletions (Knudson, 1971; Pannett and Thakker, 
2001)  Also, the gain of function associated with an oncogene is dominant, 
whilst the loss of function associated with a mutated tumour suppressor gene is 
recessive (Teich, 1997).  
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2.1.3.  Colorectal cancer 
2.1.3.1.  Introduction 
Colorectal cancer (cancer originating in either the colon or rectum) is the third 
most prevalent cancer worldwide after lung and breast cancer (World Cancer 
Report, 2003).  More than 90% of all cases of colorectal cancer are diagnosed 
in men and women over the age of 50 according to the Centres for Disease 
Control and Prevention (CDC) in the USA (Colorectal Cancer, 2006).  There 
has been little change in death rates over the last 50 years because the 
improvement in survival rates has been masked by the increase in incidence 
(Macdonald et al., 2004).  Death rates in the world’s major industrialized 
countries are shown in Table 2.2. 
 
Table 2.2 Age-adjusted death rates for colorectal cancer in the major industrialised 
countries of the world (Macdonald et al., 2004). 
 Age-adjusted death rates per 100 000 population 
Country Male Female 
Germany 21,7 17,0 
United Kingdom 18,7 13,8 
France 18,3 12,1 
Canada 16,4 11,6 
United States of America 15,9 12,0 
Japan 17,6 11,0 
Russian Federation 17,5 12,7 
 
Regular screening of the colon is crucial for the early detection of benign tissue 
masses known as polyps that can be removed before they become cancerous.  
However, screening rates are low and less than 40% of colorectal cancer cases 
are detected early.  Colonoscopy is considered to be the gold standard for 
colon cancer screening, and the American Cancer Society recommends that 
everyone should be screened regularly after the age of 50 to detect polyps 
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(Harding, 2006).  Polyps and colorectal cancer do not always cause symptoms.  
Nevertheless, symptoms do sometimes appear, such as bloody stools, 
unexplained stomach aches or cramps, and unexplained weight loss (Colorectal 
Cancer, 2006).   
2.1.3.2.  Aetiology of colorectal cancer 
A small proportion of cases of colorectal cancer are due to inheritance of certain 
mutations, although the majority of cases of colorectal cancer are sporadic (i.e. 
due to mutations arising in somatic cells and not due to inherited mutations) 
(Key et al., 1997; Macdonald et al., 2004).  A host of genes that are implicated 
in the genesis and progression of colorectal carcinomas have already been 
identified, including MYC, ras, akt, p53, APC, Smad and others.  Approximately 
85% of colorectal tumours have some sort of chromosomal instability, whereas 
the remaining 15% usually exhibit microsatellite instability or MSI (Macdonald et 
al., 2004).  Microsatellites (or short tandem repeats; STRs) are sequences of 
repeated nucleotide motifs, between 2 and 9 base-pairs in length, that are 
inserted into the normal DNA sequence.  Histological observations have led 
researchers to believe that most colorectal carcinomas are preceded by 
precancerous epithelial polyps or adenomas, and do not necessarily develop 
directly from normal epithelium, although such colorectal tumours also exist.   
 
The progression of colon carcinogenesis from benign adenomas or polyps is 
known as the adenoma-carcinoma sequence (Morson, 1974).  As time 
progressed, some oncogenes and tumour suppressor genes involved were 
assigned to the various steps of the adenoma-carcinoma sequence in a 
proposal for the progression of colorectal tumourigenesis (Fearon and 
Vogelstein, 1990).  Although it seems from this model as though mutations 
occur in a precise order, it is the accumulation of mutations which is more 
important than the order.  p53 was one of the first genes to be studied 
intensively in colorectal carcinogenesis, although it is mutated late in the 
progression from adenoma to carcinoma.  Additional lesions, the so-called 
 11
aberrant crypt foci (ACF) are believed by some researchers to be the 
intermediate between normal tissue and early adenoma (Macdonald et al., 
2004).  ACF were first described in 1987 and often contain the KRAS or APC 
mutations (Pretlow and Pretlow, 2005).  KRAS and APC mutations are thus the 
“gatekeepers” or initiators for colorectal carcinogenesis. 
 
 
Figure 2.1 The paradigm for colorectal carcinogenesis together with the relevant 
genetic markers (Macdonald et al., 2004; Pretlow and Pretlow, 2005).  
Abbreviations:  ACF:  aberrant crypt foci; APC:  adenomatous polyposis 
coli; DCC:  deleted in colorectal carcinoma; KRAS:  Kirsten rat sarcoma. 
 
Other factors involved in colorectal carcinogenesis include the loss of control 
over transforming growth factor (TGF) β as well as deregulation of the cell 
cycle.  More than 75% of cases of colorectal cancer show a loss of 
responsiveness to TGFβ, which inactivates the TGFβ signalling cascade.  This 
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could be due to either mutation of the TGFβRII gene or of the receptor.  
Mutations in genes involved in cell cycle control such as p16 and p27 have also 
been identified in a minority of colorectal cancer cases (Macdonald et al., 2004). 
 
In 10-15% of the cases of colorectal cancer, a hereditary component is at work.  
Although the underlying mechanisms are not fully understood yet, they have 
been uncovered for two distinct conditions, these being hereditary nonpolyposis 
colon cancer (HNPCC) and familial adenomatous polyposis (FAP).  FAP 
accounts for approximately 1-2% of all cases of colorectal cancer and is 
characterized by the occurrence of hundreds to thousands of benign polyps 
throughout the colon and rectum.  The polyps usually appear in early adulthood.  
Without timely intervention by the third or fourth decade of life, the probability 
that a FAP patient will develop adenocarcinoma, is close to 100% (Rose and 
Connolly, 1999; Macdonald et al., 2004). 
 
Interest in the role of nutrition in the aetiology of colorectal cancer stems largely 
from the wide variation in disease rates between populations with different 
diets. This led to the hypothesis that the contents of the colon and rectum could 
affect the risk of cancer.  It was originally suggested that starch and dietary fibre 
may protect against colorectal cancer, whilst meat or animal fat could increase 
the risk.  Results from analytical studies are in general consistent with these 
hypotheses that meat and animal fat are high-risk foods for colorectal cancer 
whereas fibre-rich foods are protective (Key et al., 1997). 
 
In addition to the effects of diet, evidence also suggests that the risk for 
colorectal cancer is reduced by physical activity as well as long-term use of 
aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs).  This effect of 
aspirin and NSAIDs probably involves inhibition of prostaglandin synthesis 
which would inhibit tumour growth and spread (Key et al., 1997). 
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Figure 2.2 The stages of initiation and progression of colorectal cancer (Roynette 
et al., 2004). 
2.2.  FATTY ACIDS AND CARCINOGENESIS 
2.2.1.  Introduction 
The notion that fatty acid intake may influence the incidence of tumourigenesis 
and cancer, has been studied intensively in vivo and in vitro for more than 30 
years and seems to be widely accepted.  Ranging from epidemiological studies 
to those conducted using cell culture models, most studies provide evidence 
that n-3 fatty acids, especially the long-chain PUFAs eicosapentaenoic acid 
(EPA) and DHA, found abundantly in fish oil, are able to inhibit the development 
of cancer or slow down tumour growth (Hardman, 2004; Larsson et al., 2004).  
However, the cellular mechanisms responsible for these effects have not yet 
been clarified, although various hypotheses exist, including modifications to 
eicosanoid metabolism and activation of different cellular signalling pathways 
(Kinsella et al., 1990; Hwang and Rhee, 1999).   
 14
RCOOH ⇔ RCOO- + H+ 
2.2.2.  Characteristics and nomenclature of fatty acids 
Lipids are molecules with a strong tendency to associate with each other 
through non-covalent interactions. These non-covalent interactions are 
responsible for the characteristic behaviour of lipid molecules in an aqueous 
environment, causing them to clump together.  The interaction of lipid molecules 
with water has vast biological importance in the formation of membranes and 
micelles.  There are two stabilizing mechanisms at work:  the hydrophobic 
interactions between the non-polar tails as well as Van der Waals interactions 
between hydrocarbon regions.  The head groups, on the other hand, are polar 
and hydrophilic and tend to associate with water (Mathews and van Holde, 
1990).  The general structure of lipids is shown in figure 2.3.   
 
 
 
 
 
 
 
 
Figure 2.3 The general structure of a lipid molecule (Voet and Voet, 1995). 
 
The simplest lipids are carboxylic acids known as fatty acids.  The structure of 
fatty acids also reflects the general structure of all lipids:  a hydrophilic 
carboxylate group is attached to a chain of hydrocarbon groups (Mathews and 
van Holde, 1990).  Naturally occurring fatty acids usually consist of an even 
number of carbon atoms (Voet and Voet, 1995).   
 
Fatty acids are weak organic acids, with pKa values averaging at approximately 
4.5.  At physiological pH, fatty acids thus exist in an anionic form: 
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When ionized, solubility in water is promoted, due to the charged carboxyl 
group which is extremely hydrophilic (Mathews and van Holde, 1990).  In figure 
3 the structure of stearate, the ionized form of stearic acid, is shown. 
 
Figure 2.4 The structure of a single stearate ion (Voet and Voet, 1995). 
 
Stearic acid is an example of a saturated fatty acid (SFA).  The carbons of the 
hydrocarbon tail of SFAs are all coupled to hydrogen atoms, and there are no 
double bonds in such tails.  SFAs form straight chains due to their lack of 
double bonds, and can thus be packed very tightly together.  Other important 
SFAs include lauric acid and palmitic acid.  SFAs with chain lengths of 4 and 6 
are known as short chain fatty acids (SCFAs), whereas SFAs with chain lengths 
of 8, 10, and 12 are medium chain fatty acids (MCFAs).  Long chain fatty acids 
(LCFAs) consist of more than 12 hydrocarbons (Mathews and van Holde, 1990; 
Fatty acid, 2006).  A list of important SFAs is given in table 2.3.   
 
 
Figure 2.5 The structure of a single oleate ion (Voet and Voet, 1995). 
 
Many important fatty acids are however unsaturated (see oleate ion in figure 
2.5).  In these fatty acids, the hydrocarbon tails contain one or more double 
bonds and are thus not “saturated” with hydrogen atoms.  Fatty acids with only 
a single double bond are known as monounsaturated fatty acids (MUFAs), 
whereas those with two or more double bonds are so-called polyunsaturated 
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fatty acids (PUFAs).  Important MUFAs and PUFAs are also given in table 2.3. 
 
Table 2.3 A summary of some biologically important fatty acids (as adapted from 
Mathews and van Holde, 1990; Bartsch et al., 1999; Larsson et al., 
2004).  Abbreviations:  MUFA, monounsaturated fatty acid; PUFA, 
polyunsaturated fatty acid; SFA, saturated fatty acid. 
Common  
Name 
IUPAC 
 Name 
Numerical 
Abbreviation 
Structural 
 Formula Source 
SFAs     
Lauric Acid n-Dodecanoic Acid 12:0 CH3(CH2)10COOH Coconut oil 
Mystiric Acid n-Tetradecanoic Acid 14:0 CH3(CH2)12COOH 
Palm kernel 
oil 
Palmitic Acid n-Hexadecanoic Acid 16:0 CH3(CH2)14COOH 
Beef fat, 
palm oil 
Stearic Acid n-Octadecanoic Acid 18:0 CH3(CH2)16COOH 
Beef fat, 
cocoa butter 
MUFAs     
Palmitoleic Acid cis-9-Hexadecenoic Acid 16:1 n-7 
CH3(CH2)5CH= 
CH(CH2)7COOH 
Macadamia 
nut oil 
Oleic Acid cis-9-Octadecenoic Acid 18:1
  n-9 CH3(CH2)7CH= CH(CH2)7COOH 
Olive oil, 
canola oil 
PUFAs     
Linoleic Acid 
cis-9,cis-12-
Octadecadienoic 
Acid 
18:2 n-6 
CH3(CH2)4CH=CHC
H2CH=CH(CH2)7CO
OH 
Sunflower 
oil, soybean 
oil 
α-Linolenic Acid 
all-cis-9,12,15-
Octadecatrienoic 
acid 
18:3 n-3 
CH3CH2CH=CHCH2
CH=CHCH2CH=CH(
CH2)7COOH 
Canola oil, 
walnut oil 
γ-Linolenic Acid 
all-cis-6,9,12-
Octadecatrienoic 
acid 
18:3 n-6 CH3(CH2)4(CH=CHCH2)3(CH2)3COOH 
Borage oil, 
Evening 
Primrose oil 
Arachidonic Acid 
all-cis-5,8,11,14-
Eicosatetraenoic 
acid 
20:4 n-6 CH3(CH2)4(CH=CHCH2)4(CH2)2COOH 
Pork fat, 
peanut oil 
Docosahexaenoic 
Acid 
all-cis-Docosa-
4,7,10,13,16,19-
hexaenoic acid 
22:6 n-3 CH3CH2(CH=CHCH2)6CH2COOH  
Fish oil 
Eicosapentaenoic 
Acid 
all-cis-5,8,11,14,17-
Eicosapentaenoic 
acid 
20:5 n-3 CH3CH2(CH=CHCH
2)5(CH2)2COOH 
Fish oil 
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The numerical abbreviations of fatty acids allow for insight into their chemical 
structures.  Such an abbreviation designates the length of the hydrocarbon 
chain, the number of double bonds, as well as the position of the double bond 
closest to the methyl end of the molecule (Roynette et al., 2004).  The carbon 
atom in this methyl group is known as the “omega” (ω) carbon, whereas the 
second carbon from the carboxyl group is referred to as the α carbon (Rose and 
Connolly, 1999).  n-3 and n-6 PUFAs are therefore also sometimes referred to 
as ω-3 and ω-6, respectively.   
 
Another system in use to assign abbreviations to fatty acids, involves the 
indication of the positions of all double bonds (as from the carboxyl end) as a 
superscript together with a Greek letter delta (Δ).  According to this 
nomenclature system, oleic acid would thus be abbreviated as 18:1Δ9 and 
arachidonic acid as 20:4Δ5,8,11,14 (Mathews and van Holde, 1990).  This method 
allows for easy identification of the IUPAC name along with the chemical 
structure, although it is not widely used. 
 
In most naturally occurring fatty acids, all double bonds are cis, which means 
that the hydrogen atoms bound to double-bonded carbons are on the same side 
of the chain.  In the cis configuration, the hydrogen atoms would repel each 
other, causing the hydrocarbon chain to bend.  The more cis double bonds in a 
chain, the more bent it appears (Voet and Voet, 1995).   
 
Fatty acids with a trans configuration (so-called trans fatty acids; TFAs) do not 
usually occur naturally.  Such MUFAs and PUFAs are produced during 
industrial processes to harden edible oils to stable products for storage and 
transportation convenience and are most often found in fast food, 
confectionaries, and hard margarines (Bartsch et al., 1999; Stender and 
Dyerberg, 2004).  Although many believe that an increased intake of TFAs is a 
health hazard and could increase the risk of developing cancer, allergies, type 2 
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diabetes and other diseases (Stender and Dyerberg, 2004), evidence to support 
this is ambiguous and TFAs will therefore not be discussed further. 
2.2.3.  Fatty acid metabolism 
2.2.3.1.  Metabolic synthesis and conversion of polyunsaturated fatty 
acids 
Most n-6 and n-3 PUFAs are synthesized from the metabolic precursor fatty 
acids, linoleic acid (LA; 18:2 n-6) and α-linolenic acid (ALA; 18:3 n-3), 
respectively.  Unlike plants, mammals do not possess the particular enzymes 
necessary for the synthesis of LA and ALA.  These fatty acids are therefore 
considered to be essential fatty acids, because they have to be consumed in 
the diet in order to maintain an adequate pool.  Vegetable seeds and oils, such 
as soybean, coconut, and sunflower oil, contain high proportions of LA, 
whereas dark green leafy vegetables as well as linseed, canola, walnut, and 
blackcurrant seed oils are good sources of ALA (Bartsch et al., 1999; Roynette 
et al., 2004). 
 
In order to yield more n-6 unsaturated fatty acids from LA, it is first desaturated 
to γ-linolenic acid (GLA; 18:3 n-6) by the enzyme Δ6 desaturase.  Thereafter, 
the molecule is elongated by 2 carbon atoms to dihomo-γ-linolenic acid (DGLA; 
20:3 n-6).  DGLA is subsequently desaturated by the action of Δ5 desaturase to 
yield arachidonic acid (AA; 20:4 n-6) (Whelan and McEntee, 2004).   
 
The metabolism of the precursor ALA to produce more n-3 PUFAs is fairly 
similar to the process just described and involves the same enzymes.  The 
enzyme Δ6 desaturase firstly catalyzes the conversion of ALA to stearidonic 
acid (SDA; 18:4 n-3), which is subsequently elongated and desaturated to EPA 
(20:5 n-3).  Following a series of steps including elongation, desaturation and β-
oxidation, DHA (22:6 n-3) is produced (Whelan and McEntee, 2004).   
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Figure 2.6 Metabolism of linoleic acid and α-linolenic acid  to yield arachidonic acid 
and docosahexaenoic acid, respectively (Rose and Connolly, 1999; 
Whelan and McEntee, 2004).  Abbreviations:  AA, arachidonic acid; 
ALA, α-linolenic acid; DGLA; dihomo-γ-linolenic acid; DHA, 
docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, 
eicosapentaenoic acid; GLA, γ-linolenic acid; LA, linoleic acid; SDA, 
stearidonic acid. 
 
There exists competition between n-6 and n-3 PUFAs as substrates for the 
desaturase and elongase enzymes that are common to both metabolic 
pathways (Rose and Connolly, 1999).  The enzymes have a greater affinity for 
n-3 PUFAs, which implicates the preferential metabolism of those fatty acids, 
given that the dietary intake of n-3 PUFAs is high.  This leads to a “competitive 
inhibition” of n-6 PUFA metabolism (Roynette et al., 2004).   
2.2.3.2.  Eicosanoid metabolism 
n-6 and n-3 PUFAs have crucial functions in the body, especially as 
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phospholipids that comprise biological membranes.  They also modulate 
membrane fluidity (an increased number of PUFAs in the membrane increases 
fluidity), cell signalling pathways, and cellular interaction.  However, their most 
vital role is arguably immune regulation, because certain PUFAs, both n-6 and 
n-3, are metabolic precursors for the synthesis of eicosanoids (Roynette et al., 
2004).   
 
Eicosanoids are biologically potent, short-lived, hormone-like lipids with chain 
lengths of 20 carbon atoms.  These molecules are crucial in the modulation of 
immune responses, especially inflammation, platelet aggregation, cellular 
growth, and differentiation.  The fatty acids that are the precursors for 
eicosanoid synthesis are DGLA, AA, and EPA.  Before conversion of these fatty 
acids can take place, the fatty acids need to be liberated from phospholipids in 
biological membranes by the so-called phospholipase enzymes.  Then, the fatty 
acids are converted by cyclooxygenase (COX) or lipoxygenase (LOX) to 
different types of eicosanoids.  COX gives rise to prostaglandins (PGs) and 
thromboxanes (TXs), collectively known as prostanoids.  There are two known 
isoforms of the COX enzyme:  COX-1, which is constitutively expressed in most 
tissues and considered to generate PGs for tissue homeostasis, and COX-2, an 
inducible enzyme which is up regulated in response to inflammatory cytokines, 
growth factors and tumour promoters (Larsson et al., 2004; Sinicrope and Gill, 
2004). The eicosanoids produced by  the LOX enzyme, which also has different 
isoforms, are known as leukotrienes, hydroxy fatty acids, and lipoxins (Larsson 
et al., 2004).   
2.2.3.2.a)  Arachidonic acid-derived eicosanoids 
Because AA is the major PUFA in cell membranes, most eicosanoids are AA 
derivatives.  These eicosanoids comprise the 2-series prostanoids and 4-series 
leukotrienes.  As the numerical prefixes denote the number of double bonds, 
these molecules thus have two and four double bonds, respectively.   
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COX firstly converts AA to PGG2 (the subscript also indicates the number of 
double bonds present), which is subsequently reduced to PGH2 by the 
peroxidase activity of COX.  PGH2 is thereafter the precursor for various 
prostanoids:  PGD2, PGE2, PGF2, TXA2, and PGI2.  The PGs have a wide range 
of biological functions, although specific cells are usually highly selective 
regarding the prostanoids formed following the production of PGH2.  For 
example, vascular endothelial cells produce mainly PGI2, which inhibits platelet 
activation and aggregation (Rose and Connolly, 1999). 
 
LOX inserts molecular oxygen into AA to produce 5-, 12-, or 15-
hydroperoxyeicosatetraenoic acid (HPETE), depending on the corresponding 
LOX-isoform responsible for the conversion (i.e. 5-, 12-, or 15-LOX).  HPETE is 
thereafter reduced to the corresponding hydroxyeicosatetraenoic acid (HETE).  
The HETEs’ functions include immune responses, ion transport, and hormone 
secretion.  However, 5-HPETE is also converted to leukotriene A4 (LTA4), which 
undergoes further reactions to produce LTE4 and LTB4.  Leukotrienes are 
believed to be involved in the pathogenesis of asthma, cystic fibrosis, and 
pulmonary hypertension (Rose and Connolly, 1999; Larsson et al., 2004). 
 
Generally, AA-derived eicosanoids are pro-inflammatory, although PGE2 has 
been suggested to have anti-inflammatory properties.  AA-derived eicosanoids 
have also been positively linked to carcinogenesis (Larsson et al., 2004). 
2.2.3.2.b)  Eicosapentaenoic acid-derived eicosanoids 
EPA-derived eicosanoids are the 3-series prostanoids and 5-series 
leukotrienes, thus having 3 and 5 double bonds in their structure, respectively.  
The production of these EPA-derived molecules involves many of the same 
enzymes involved in AA-derived eicosanoid metabolism. 
 
COX converts EPA to PGH3, which is then further metabolized to PGE3, PGI3, 
and TXA3.  PGI3 and TXA3 are thereafter converted to the inactive metabolites 
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Δ17-6-keto-PGF1α and TXB3, respectively (Rose and Connolly, 1999). 
When the 5-LOX enzyme acts upon EPA, LTA5 is produced. This is thereafter 
metabolized to LTB5.  However, LTB5 has only 5-10% of the activity of its AA-
derived counterpart, LTB4.  All EPA-derived eicosanoids are considered to be 
anti-inflammatory (Rose and Connolly, 1999). 
 
EPA competes with AA as the substrate of both the COX and LOX enzymes.  
As with the desaturases and elongases, EPA is once again the preferred 
substrate.  Thus, increased dietary intake of EPA leads to decreased 
generation of AA-derived eicosanoids as well as an elevation in the generation 
of EPA-derived mediators (Calder and Grimble, 2002; Roynette et al., 2004).  
Following supplementation with ALA, EPA or DHA, phospholipid-AA 
concentrations are significantly decreased, which has implications for 
eicosanoid production, since n-3 PUFAs would be incorporated into membrane 
phospholipids at the expense of AA (Calder and Grimble, 2002).  This 
effectively decreases the availability of AA as eicosanoid precursors.  
Supplementation with those fatty acids also leads to the inhibition of LA 
desaturation and subsequently decreased AA concentrations (Roynette et al., 
2004).  Thereby the production of EPA-derived eicosanoids is favoured at the 
expense of AA-derived eicosanoids (Larsson et al., 2004). 
 
Furthermore, n-3 PUFAs also enhance the breakdown of eicosanoids.  The 
generation of AA-derived eicosanoids is not inhibited only by n-3 PUFAs, but 
also by the eicosanoids derived from them, and some of these eicosanoids 
have an even stronger inhibitory effect than that of EPA (Larsson et al., 2004).   
2.2.4. The anti-tumourigenic and anti-carcinogenic effects of  
n-3 polyunsaturated fatty acids 
2.2.4.1.  The n-6/n-3 imbalance 
Omega-3 (n-3) fatty acids are known to be protective against a host of diseases 
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such as cardiovascular disease (CVD), inflammation, neurodegenerative 
diseases and especially cancer (Akbar et al., 2005; Kang, 2005).  However, the 
typical Western diet consumed today seems to be deficient in these important 
PUFAs, resulting in an increased risk for modern diseases such as those 
mentioned previously.  In addition to the apparent n-3 PUFA deficiency, the 
Western diet has elevated n-6 PUFA content, especially LA and AA (Rose and 
Connolly, 1999; Kang, 2005).  It is believed that the foods available to our 
ancestors (before agricultural practices and animal domestication were taken 
on) were rich in n-3 PUFAs and contained them in a ratio with n-6 PUFAs of 
approximately 1:1.  Such a fatty acid profile in food led the human body to 
establish a genetic pattern without genes that would enable it to synthesize fatty 
acids or convert them to another form.  It seems that the n-6:n-3 PUFA ratio has 
increased over time, as the Western diet today contains a ratio of 15–20:1.  
Unfortunately, the human body cannot adjust its genome to suit such a lipid 
profile in such a short time, making modern man susceptible to modern, 
devastating disorders.  It is thus necessary to supplement our diets to enrich 
tissues with n-3 fatty acids and correct for the n-6/n-3 imbalance.  Lower 
organisms such as plants, microorganisms, and the roundworm C. elegans are 
able to convert n-6 to n-3 PUFAs, and certain genes responsible for this 
conversion (such as fat-1) have already been successfully cloned and 
introduced into mammalian cells and animal models (Simopoulos, 1991; 
Bartsch et al., 1999; Kang, 2005). 
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Figure 2.7 An overview of the metabolism of arachidonic acid-derived eicosanoids 
(Larsson et al., 2004).  Abbreviations:  LA, linoleic acid; AA, arachidonic 
acid; PLA2, phospholipase A2; COX, cyclooxygenase; LOX, 
lipoxygenase; PG, prostaglandin; HPETE, hydroperoxyeicosatetraenoic 
acid; HETE, hydroxyeicosa-tetraenoic acid; LT, leukotrienes; TX, 
thromboxane.   
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Figure 2.8 An overview of the metabolism of eicosapentaenoic acid-derived 
eicosanoids (Larsson et al., 2004).  Abbreviations:  DHA, 
docosahexaenoic acid; ALA, α-linolenic acid; EPA, eicosapentaenoic 
acid; PLA2, phospholipase A2; COX, cyclooxygenase; LOX, 
lipoxygenase; PG, prostaglandin; HPEPE, hydro-
peroxyeicosapentaenoic acid; HEPE, hydroxyeicosapentaenoic acid; 
LT, leukotrienes; TX, thromboxane.   
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2.2.4.2.  The role of fatty acids as constituents of membrane 
phospholipids in normal and tumour cells 
The fatty acids contained in membrane phospholipids are essential in 
determining certain membrane physical properties such as fluidity and flexibility.  
They also regulate cellular functions, including the movement of ions and 
metabolic products across the membrane, receptor binding and eicosanoid 
production (Spector and Burns, 1987).   Mammalian cells in vitro readily take up 
lipids such as fatty acids from their culture medium (Spector and Yorek, 1985), 
especially the serum component.  Supplementation of media with different fatty 
acids is thus a simple method to manipulate the fatty acid composition of 
membrane phospholipids in cultured cells.   
 
Although the cells are then often cultured in serum-free medium to abolish 
interference from serum lipids (Nano et al., 2003), extensive changes in the 
phospholipid composition can also be achieved in the presence of serum.  The 
type of serum is also of importance.  For example, foetal calf (a.k.a. bovine) 
serum (FCS or FBS) contains approximately 65% less PUFAs than horse 
serum.  Modification of membrane phospholipids can also be achieved by 
supplementation of media with intact phospholipid vesicles, sphingolipids, or 
even cholesterol (Spector and Yorek, 1985). 
 
When membrane phospholipid composition is modified, so are various cellular 
processes and responses.  These include carrier-mediated transport, activities 
of membrane-bound enzymes, binding properties of membrane receptors, 
cytotoxicity, growth, modulation of cellular signalling events, and eicosanoid 
synthesis, amongst others (Spector and Yorek, 1985; Spector and Burns, 1987; 
Kang, 2005). 
2.2.4.3.  In vitro studies on the effects of fatty acids on cancer cell lines 
The research group of Begin and colleagues performed some of the earliest 
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studies showing that PUFAs kill human tumour cells in vitro.  These tumour 
cells were derived from breast, lung, and prostate carcinomas.  Their studies 
also investigated the effect of various fatty acids on co-cultures of tumour cells 
and normal fibroblasts or other normal cells.  In these co-culture systems, 
supplementation with EPA, GLA, or AA led to the selective death of malignant 
cells.  Although the normal cells were not killed and outgrew the malignant cells, 
their rate of division was lowered.  In contrast with PUFAs, SFAs and MUFAs 
did not have any cytotoxic effects on malignant cells (Begin et al., 1985; Begin 
et al., 1986; Das et al., 1987).   
 
The validity of these studies was later often questioned because the “normal” 
cell lines used were either human fibroblasts or derived from different tissues 
and different species.  The possibility of tissue and species specific effects were 
therefore not taken into consideration when it was concluded that PUFAs exert 
their cytotoxic effects only on tumour cells (Diggle, 2002).  Nevertheless, the 
cancer-specificity of PUFAs’ cytotoxicity was shown in 1998 when GLA was 
tested in astrocytoma cells (Vartak et al., 1998).  Although GLA killed the 
astrocytoma cells, “normal” astrocytes were protected.  Both cell lines were also 
of murine origin, thus concurrently eliminating possible species specific as well 
tissue specific effects. 
 
As these studies found that both n-3 (such as EPA) and n-6 (such as AA) 
PUFAs killed cancer cells, the researchers speculated that the number of 
double bonds was the determining factor of the cytotoxic potential of particular 
fatty acids.  They also suggested that those PUFAs with three, four, or five 
double bonds were most effective, whereas DHA (which contains six double 
bonds) was least effective (Begin and Ells, 1987; Begin et al., 1988).  Today, 
however, it is believed that the class of the PUFA, i.e. whether it is n-3 or n-6, 
as well as chain length are the determining factors of cytotoxicity, rather than 
the number of double bonds.  This could explain the dramatic effects observed 
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in most in vitro studies with the use of DHA throughout the years of research in 
this field (Rose and Connolly, 1991; Sagar et al., 1992; Siddiqui et al., 2001; 
Nano et al., 2003). 
 
It has already been speculated in early studies that the cytotoxic effects of 
certain fatty acids such as EPA might be, at least partially, due to enhanced 
free radical generation (Das et al., 1987a; Das et al., 1987b).  In fact, the 
addition of vitamin E to cancer cell cultures reduced the efficacy of PUFAs 
(Begin et al., 1988; Falconer et al., 1994; Chen and Istfan, 2000; Nano et al., 
2003).  It therefore seems quite likely that oxidative stress is a major role-player 
in PUFA-induced cytotoxicity in tumour cells.  Still, the question whether a 
similar mechanism is at work in normal cells and why they tend to be unharmed 
by it, remains unanswered.   
 
Although these early studies uncovered the cytotoxic abilities of PUFAs in vitro 
and aimed to explore the effects of using different concentrations on a variety of 
cell lines, a much-needed shift occurred in the late nineties.  The objective of 
research was thereafter to uncover the underlying mechanisms responsible for 
the PUFAs’ effects.  Numerous malignant cell lines were supplemented with 
different fatty acids and efforts made to attribute the findings to cellular events 
such as apoptosis, cellular signalling, alterations in eicosanoid production, 
increased oxidative stress, cell cycle arrest, and changes in membrane 
phospholipid composition (Conklin, 2002; Hardman, 2002).  However, despite 
all these attempts, an understanding of the precise cellular events modulated by 
exogenous fatty acid treatment is still elusive.  It is likely that it is not an isolated 
mechanism at work, but a collection of processes including those mentioned 
earlier and particularly signalling pathways.   
2.2.4.4.  Experimental evidence from animal models  
Although in vitro models are arguably the most useful to gain insight into the 
selective cytotoxicity of certain fatty acids and their underlying mechanisms, 
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animal models are better suited for the study of cancer incidence and 
progression and how it could be influenced by fatty acid intake. Animal models 
have been described for a host of cancer subtypes, including breast, colon, and 
prostate cancer.  The studies have already shown convincingly that n-3 PUFAs 
are effective agents to inhibit or suppress tumour growth, whereas n-6 PUFAs 
stimulate the growth of tumours.  The in vitro studies, on the other hand, deliver 
more conflicting results, as it is often found that n-6 PUFAs are equal to n-3 in 
their ability to kill tumour cells.  In general, though, the n-6 PUFAs are 
associated with the enhancement of tumourigenesis, whereas long-chain n-3 
PUFAs such as DHA have profound inhibitory effects (Rose, 1997; Bartsch et 
al., 1999).   
 
There exist numerous protocols to induce cancer in experimental animals, 
ranging from exposure to known carcinogens to genetic engineering.  The use 
of nude mice injected with cancer cells to induce malignancies is arguably the 
most popular way to produce models for cancer, because they cannot reject 
any grafts. 
 
A recent study from the laboratories of Hardman and colleagues found that a 
diet rich in n-3 PUFAs could reduce the growth rate of breast tumours, as well 
as tumour angiogenesis (Hardman et al., 2005).  In this study, nude mice 
received mammary injections of MDA-MB-231 cells, a human breast cancer cell 
line.  Following tumour establishment, half the mice were fed a diet high in n-3 
PUFAs and half were fed an n-6 PUFA-rich diet.  When the rate of tumour 
growth was analyzed, the n-3 diet effectively decreased tumour growth and also 
suppressed tumour angiogenesis.  The n-6 diet, on the other hand, dramatically 
increased the tumour growth rate.  In fact, the effect of the n-3 diet on tumour 
growth rate was equal to that produced with gamma irradiation.   
 
In a much earlier study, also done in nude mice receiving breast cancer cell 
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grafts, the researchers found that DHA and EPA also effectively suppress the 
metastases of tumour cells in addition to reducing tumour size (Rose and 
Connolly, 1993; Rose et al., 1995).  It was also found that an EPA 
supplemented diet seemed superior to a DHA supplemented diet in limiting 
metastasis at a low concentration, whereas no differences occurred between 
the diets when containing higher concentrations of either fatty acid (Rose et al., 
1995). 
 
n-3 PUFAs are also able to increase the efficiency of chemotherapeutic drugs.  
In a study done on nude mice bearing MDA-MB-231 tumour cell grafts, tumour 
growth was more effectively decreased in mice receiving fish oil 
supplementation together with doxorubicin chemotherapeutic treatment than in 
those treated with doxorubicin alone (Hardman et al., 2001).  The amount of 
fish oil fed to the experimental animals was equivalent to the amount fit for 
human consumption without intolerable gastrointestinal side-effects (Burns et 
al., 1999).   
 
The effect of fatty acid supplementation on the progression of colon cancer in 
rats is often studied with the use of azoxymethane, a potent carcinogen that 
induces colon tumours.  When F344 rats were treated with azoxymethane and 
fed different diets, tumour incidence was dramatically reduced in those animals 
fed a fish oil supplemented diet rich in EPA and DHA.  This diet also reduced 
tumour multiplicity, i.e. the number of tumours formed per rat.  Both incidence 
and multiplicity of tumours were increased in rats fed a corn oil diet (Reddy and 
Sugie, 1988), reaffirming the tumour enhancing effects of the n-6 series PUFAs.  
In a more recent study it was confirmed that a diet rich in n-6 PUFAs led to 
higher incidence and multiplicity of colonic tumours in azoxymethane-treated 
F344 rats (Rao et al., 2001).   
 
The metastasis of colonic tumour cells to secondary sites is also inhibited by n-
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3 PUFAs.  This was shown in F344 rats bearing colon tumours from ACL-15 cell 
grafts.  In rats receiving EPA treatment, metastasis of the cancer cells to the 
liver was inhibited, compared with a group receiving LA treatment (Iwamoto et 
al., 1998).   
 
However, the question is not only whether n-3 PUFAs are able to reduce the 
appearance or metastasis of malignant tumours, but also whether it could 
reduce the risk for tumourigenesis to start with.  This would be denoted by a 
reduced incidence of those biomarkers known to show an increased risk, such 
as the appearance of aberrant crypt foci (ACF) in the colon as a definite sign of 
high risk to develop colon cancer.  In fact, a fish oil rich diet was indeed 
effective in reducing the appearance of ACF in both the proximal and distal 
colon regions of azoxymethane-treated F344 and Sprague-Dawley rats, 
respectively (Takahashi et al., 1997; Coleman et al., 2002).  Importantly, when 
the fish oil diet was combined with the ingestion of α-cellulose, the ACF-
reducing effect of the fish oil was augmented (Coleman et al., 2002).  This 
amplification effect could be ascribed to the beneficial effect of a high fibre diet 
on a reduced risk of colon cancer (Howe et al., 1992).   
 
ACF formation and growth was also successfully reduced by treatment with 
DHA alone.  When DHA were administered intragastrically during as well as 
after treatment with a specific carcinogen, the number of ACF formed as well as 
the mean number of aberrant crypts per focus, were significantly reduced 
(Takahashi et al., 1993; Takahashi et al., 1997).   
 
From the evidence given it thus seems that, in animal models, an EPA or DHA 
rich diet is able to reduce the formation of tumours, as well as retard their 
growth.  The efficacy of n-3 PUFAs in this regard can be investigated by 
transferring animals to experimental diets either before or during carcinogen 
treatment or following tumour induction.  However, the majority of animal 
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studies on this subject involve the assignment of animals to experimental diets 
before the onset of carcinogen treatment.  Nevertheless, in 1991 Reddy et al. 
published their findings on the effect of n-3 and n-6 rich diets during the 
initiation (two weeks before first treatment with carcinogen) and post-initiation 
(three days after final treatment) stages of colon tumour induction.  It was found 
that an n-3 rich diet either during initiation or post-initiation stages significantly 
reduced tumour incidence as well as multiplicity, whereas the n-6 rich diet 
during post-initiation significantly elevated tumour incidence and multiplicity.  
The n-6 diet had no effect during the initiation phase (Reddy et al., 1991).  
However, this study failed to show that n-3 PUFAs are able to reduce the size of 
established tumours.   
 
In the study by Hardman et al. in 2005 (referred to in an earlier paragraph) 
animals were indeed assigned to different experimental diets five weeks after 
final treatment with MDA-MB-231 cells.  Tumour growth was monitored to 
ensure that the breast tumours were in fact established before the effects of 
either an n-3 or n-6 rich diet were investigated.  The study then showed that the 
n-3 rich diet significantly reduced mammary tumour growth rate and size, 
whereas the n-6 rich diet accelerated tumour growth and caused increased 
tumour size (Hardman et al., 2005).  Although this study convincingly showed 
the effects of fatty acids on already established tumours, more such studies are 
required, because the scenario of either a change in diet or n-3 PUFA 
supplementation following the diagnosis of cancer would be much more 
relevant.   
2.2.4.5. Epidemiological evidence for link between diet and cancer 
incidence 
Epidemiological studies have demonstrated a lower incidence of certain 
malignancies amongst certain populations.  This phenomenon was most 
notably described in the Eskimo population of Greenland (Blot et al., 1975; 
Lanier et al., 1976; Lanier et al., 1980; Lanier et al., 1982).  The typical 
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Greenland Eskimo diet is high in lipids and contains predominantly large 
quantities of seal and fish and is rich in PUFAs, especially EPA and ALA (Bang 
et al., 1976; Bang et al., 1980).  When the plasma lipids of native Greenland 
Eskimos were analyzed and compared to that of Danes and of Eskimos living in 
Denmark, the native Eskimos had higher plasma lipid concentrations of LA of 
the n-6 series, and ALA, EPA, and DHA of the n-3 series (Dyerberg et al., 
1975).  During this time, much attention was given to the proposal that such a 
plasma lipid profile was favourable towards a decreased incidence of 
atherosclerosis and ischaemic heart disease (IHD) (Dyerberg et al., 1975; 
Dyerberg and Bang, 1979).  However, other research groups were focusing on 
the decreased cancer risk among Eskimos and other Alaskan natives, such as 
the Aleuts.  These cancers included those of the lung, larynx, bladder, prostate, 
breast, and other sites (Lanier et al., 1976).  Yet as time passed the cancer 
profile of these populations changed markedly to resemble that of the American 
Caucasian population (Lanier et al., 1982; Lanier et al., 2001), which might be 
due to the adaptation of a Western lifestyle or the fact that the average age of 
the Alaskan population is increasing.  Nevertheless, those early studies of the 
dietary habits of the Greenland inhabitants and the once rarity of cancer 
amongst them, led to the first suggestions of possible anti-carcinogenic effects 
of PUFAs.   
 
A related phenomenon was also seen amongst the population of the 
Mediterranean countries such as Greece, where olive oil is an important part of 
the diet (Berrino and Muti, 1989; Kushi et al., 1995; Trichopoulou and Lagiou, 
1997; Trichopoulou et al., 2000).  This oil is essentially composed of oleic acid 
(OA), a long chain MUFA.  However, olive oil also contains high levels of 
antioxidants (Visioli et al., 1998; Wahle et al., 2004) which may be accountable 
for its beneficial effects, rather than the OA content. 
2.2.4.6.  Clinical trials on n-3 fatty acid supplementation 
Since fatty acids are safe for human consumption and appropriate dosages are 
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known, it can be concluded from animal studies that n-3 supplementation would 
be a beneficial addition to conventional cancer therapy, although more clinical 
trials need to be carried out. 
 
Some clinical trials to investigate the effect of PUFA supplementation have 
been done on cancer patients and subjects with a high cancer risk.  In one of 
these, high doses of GLA were administered in the form of evening primrose oil 
to cancer patients.  The GLA successfully prolonged the lives of patients 
suffering from liver, breast, brain and oesophageal cancers without any side-
effects (Van der Merwe et al., 1987; van der Merwe et al., 1990). 
 
Nonetheless, despite evidence from various models supporting the anti-
tumourigenic effect of PUFAs, few studies have investigated the molecular 
mechanisms responsible for these effects.  This is surprising, as it is well 
established that fatty acids can modulate the activities of various enzymes 
involved in signal transduction, such as protein kinase C (PKC) and 
phospholipases (Sumida et al., 1993; Murray et al., 2002) as well as ion 
channels (Chow and Jondal, 1990; Ordway et al., 1991).    
2.3.  SIGNAL TRANSDUCTION AND CANCER 
2.3.1.  Introduction 
Signal transduction concerns the mechanisms whereby external influences 
determine cellular activities and enable the exchange of information between 
the cell membrane and the cytosol.  Such information exchange mechanisms 
are crucial in higher organisms to regulate and coordinate cellular processes 
such as division and differentiation, and conveying sensory information such as 
stress, vision etc. (Krauss, 2003).  Since the deregulation of these intracellular 
signalling pathways is often implicated in the development of cancer and other 
diseases, an understanding of the signalling mechanisms involved in normal 
cellular activities such as proliferation and differentiation is important for greater 
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insight into the abnormal growth of tumour cells.   
 
Specialised mechanisms to relay external information into the cell are crucial 
since the plasma membrane presents a barrier to the extracellular environment 
to alter cellular response directly.  This is because most “signals” (or so-called 
first messengers), such as growth factors and many hormones, are hydrophilic 
and will therefore not pass through the phospholipid bilayer of the plasma 
membrane.  In contrast, steroid hormones, eicosanoids, etc. are hydrophobic 
and will cross membranes to interact with intracellular receptors.  To overcome 
the problem, hydrophilic substances bind to receptors located on the surfaces 
of their target cells.  A mechanism by which first messengers can direct and 
control intracellular physiological changes thus evolved together with the 
appearance of cell-surface receptors.  (Gomperts et al., 2003).   
2.3.2.  Activation of cell-surface receptors  
The activation of receptors on the cell surface can elicit a variety of cellular 
responses including proliferation, migration, differentiation, changes in 
metabolism, and apoptosis (Schlessinger and Ullrich, 1992), depending on the 
nature of the extracellular ligand and the receptor.  In order to bring forth 
physiological changes within a cell, the activated receptor firstly interacts with 
another protein such as a tyrosine kinase, a GTP-binding protein (G-protein), or 
an ion channel, depending on the nature of the receptor. 
2.3.2.1.  Tyrosine kinase receptors 
Many receptors, such as those for platelet-derived growth factor (PDGF) and 
epidermal growth factor (EGF), have an intrinsic tyrosine kinase activity.  Upon 
ligand interaction, these so-called tyrosine kinase receptors (TKRs) cannot 
function as monomers to initiate signalling pathways and therefore the 
receptors will form either dimers or oligomers (Hwang and Rhee, 1999; 
Gomperts et al., 2003).  Following dimerization (or oligomerisation), TKRs will 
autophosphorylate different tyrosine amino acid residues firstly in their 
 36
cytoplasmic domains and thereafter in their kinase domains, leading to 
activation.  The activated TKRs will then also phosphorylate tyrosine residues 
on other transducing proteins (Carpenter, 1987).  The autophosphorylated 
tyrosine residues serve as docking sites for proteins with Src homology 2 (SH2) 
domains, which are highly conserved regions present in many transducing and 
adaptor molecules (Hwang and Rhee, 1999).  Following the recruitment of 
certain molecules, a cascade of protein interaction and activation by means of 
phosphorylation (or other types of modification) ensues, which conveys the 
information to the nucleus in order to elicit a physiological response such as 
gene expression (see figure 2.9). 
2.3.2.2.  G-protein coupled receptors 
G-protein coupled receptors (GPCRs) represent the largest group of 
transmembrane receptors and interact with ligands such as adrenaline, 
noradrenaline, luteinising hormone (LH), and bradykinin.  The GPCR typically 
consists of seven transmembrane helices in close proximity to a G-protein, 
hence the name of these receptors (Krauss, 2003).  Activation of GPCRs is 
often followed by the rapid generation of so-called second messengers such as 
diacylglycerol (DAG), cyclic AMP (cAMP), calcium ions, nitric oxide (NO), and 
phosphoinositides (PIs) (Berridge, 1984; Berridge, 1988; Krauss, 2003) by 
specific effector enzymes.  The second messengers subsequently activate a 
cascade of kinases, ultimately leading to different cellular responses. 
2.3.3.  Major cellular signalling pathways 
For the purposes of this dissertation, the following pathways will be discussed: 
ERK1/2, p38 MAPK, Akt, and p53, as well as the mechanisms of apoptosis.   
 
Both ERK (extracellular regulated kinase)1/2 and p38 are members of the 
mitogen-activated protein kinase (MAPK) family, together with JNK (c-jun NH2-
terminal kinase; also known as stress-activated protein kinase or SAPK), ERK3, 
ERK4, ERK5, NLK (nemo-like kinase) and other lesser known kinases (Pearson 
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et al., 2001).  The MAPKs are closely related Ser/Thr kinases activated by a 
cascade downstream of both TKRs (by e.g. insulin) and GPCRs (by e.g. 
angiotensin II) (Lopez-Ilasaca, 1998; Pearson et al., 2001).   
 
 
Figure 2.9 General steps in receptor-mediated signal transduction pathways via 
tyrosine kinase receptors (Hwang and Rhee, 1999).  Abbreviations:  
SH2:  Src homology 2. 
Dimerisation or oligomerization of receptors by ligand binding 
Autophosphorylation of tyrosine residues in cytoplasmic domain of 
receptors 
Recruitment of signal transducers possessing SH2 domains 
Kinase cascade 
Phosphorylation of transcription factors 
Translocation of transcription factors to nucleus 
Gene expression 
Cellular response 
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Figure 2.10 General steps in receptor-mediated signal transduction via G-protein 
coupled receptors. 
 
Generation of second messengers 
Activated receptor activates G-protein 
Kinase cascade 
Phosphorylation of transcription factors 
Translocation of transcription factors to nucleus 
Gene expression 
Cellular response 
Activated subunit of G-protein dissociates and activates effector 
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Figure 2.11 Structure of a transmembrane G-protein coupled receptor (Krauss, 
2003) 
 
Akt, also known as protein kinase B (PKB), is also a Ser/Thr kinase.  It is 
activated downstream of both TKRs and GPCRs via a specific enzyme known 
as phosphoinositide 3-kinase (PI3K) (Krauss, 2003; Scheid and Woodgett, 
2003).  The Akt pathway is involved in cellular processes including proliferation, 
differentiation, and metabolism, and is fundamental to cellular survival by 
means of the suppression of apoptosis (Nicholson and Anderson, 2002). 
 
p53 was mentioned earlier when it was stated that the p53 gene is often 
mutated in cancer cells.  In fact, more than 50% of human tumours bear a 
mutated form of p53 (Nigro et al., 1989).  This was the first indication that p53 
must serve critical functions within cells to ensure normal control of division.  
Overall, p53 serves to protect the cell from the potentially damaging 
consequences of various stresses, e.g. hypoxia and irradiation, which is why it 
is a normal mechanism of defence against tumour induction (Krauss, 2003). 
 
N
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Apoptosis (a.k.a. programmed cell death) is a type of cell death which has been 
defined both morphologically and biochemically.  The morphological features of 
this process have been well described and can be observed in fixed and 
stained tissues, or in cultured cells.  With regard to its biochemical 
characteristics, numerous apoptosis-related genes and their products have 
been uncovered (Kiechle and Zhang, 2002).  Although apoptosis is essential for 
normal physiological functioning, it is also deeply involved in the pathogenesis 
of many diseases, such as cancer and cardiovascular diseases (Cho and Choi, 
2002). 
2.3.3.1.  ERK 1/2 
MAPK pathways are organized in cascades consisting of three core signalling 
modules which transmit signals by sequential phosphorylation events (Kyriakis 
and Avruch, 2001; Pearson et al., 2001).  Incoming signals (such as the 
activation of a receptor by a particular ligand) are received by an initial 
upstream protein kinase.  From there, the signal is subsequently transmitted to 
another kinase which in turn activates the terminal protein kinase(s).  In the 
ERK pathway, ERK1 and ERK2 (also known as p44 and p42 MAPK, 
respectively) are the terminal kinases (Pearson et al., 2001; Krauss, 2003).   
 
ERK1 and ERK2 are approximately 85% homologous, with even greater 
homology in their core regions involved in substrate binding (Pearson et al., 
2001).  Because ERK1 and ERK2 are believed to have overlapping, and 
perhaps redundant, signalling capabilities, they are frequently simply referred to 
as ERK1/2 (Cobb and Goldsmith, 2000).  ERK1 and ERK2 are both 
ubiquitously expressed, although their relative abundance varies across 
different tissue types (Pearson et al., 2001).  Although they were historically 
believed to be essentially interchangeable due to their seemingly overlapping 
functions, knock-out studies have proven this to be incorrect.  Whereas ERK1 
deficient mice are viable with only minor defects in T cell maturation, ERK2 
deficient mice die early in development, proving that ERK1 cannot compensate 
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for ERK2 during embryogenesis (Saba-El-Leil et al., 2003; Pages and 
Pouyssegur, 2004). 
 
The kinase immediately upstream of ERK1/2 in the cascade is a member of the 
MEK (MAP/ERK kinase, also known as MAPK-kinase or MAPKK) family of 
kinases.  These are dual specificity protein kinases able to phosphorylate their 
substrates on tyrosine as well as serine or threonine residues.  MEK 
phosphorylates ERK on a TEY motif (threonine and tyrosine residues separated 
by a single glutamate residue) in the activation loop of subdomain VIII of the 
kinase domain (Payne et al., 1991; Kyriakis and Avruch, 2001), with the tyrosine 
residue being phosphorylated first (Ferrell and Bhatt, 1997).  In fact, 
phosphorylation of threonine takes place only after the accumulation of a 
certain quantity of tyrosine-phosphorylated ERK1/2 protein, known as the 
accumulation threshold.  Once it is reached, the threonine residues are 
phosphorylated and ERK molecules are subsequently activated.  It is generally 
believed that this mechanism of activation of ERK (and the other MAPKs) 
serves to enhance the cooperativity of MAPK activation and to allow modulation 
by other signalling events, in addition to amplification of the signal from MEK 
(Pearson et al., 2001).  Several members of the MEK family can also be 
phosphorylated by kinases in other pathways, enabling crosstalk (Mansour et 
al., 1994).   
 
However, the entry point of the ERK pathway is at a kinase which precedes 
MEK.  MAP3K (also known as MEK kinase, MEKK, or MAPKKK) 
phosphorylates members of the MEK family at two specific serine residues in a 
conserved NSXANS motif (where X represents any amino acid) (Krauss, 2003) 
following the formation of MAP3K homo-oligomers (Kyriakis and Avruch, 2001).  
Representatives of the MAP3K family include Raf, Mos, and MEKK1-3.  The 
proteins that recruit and phosphorylate MAP3K are most often small GTPases 
such as Ras or members of the Rho/Rac family, although other protein kinases 
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can also deliver the entry point signals.  If another protein kinase is indeed 
responsible for the phosphorylation of MAP3K and the commencement of the 
kinase cascade, it is referred to as a MAP4K (thus a MAP3K kinase) 
(Hagemann and Blank, 2001; Krauss, 2003).   
 
ERK was the first mammalian MAPK to be identified.  This pathway is largely 
regulated by Ras, a monomeric GTPase, which recruits isoforms of Raf (the 
MAP3K).  The Raf family of kinases is composed of the three isoforms:  A-Raf, 
B-Raf, and the ubiquitously expressed Raf-1 (Kyriakis and Avruch, 2001; 
Pearson et al., 2001). Raf activates MEK1 and MEK2 (MAPKKs) in turn, which 
activates ERK1 and ERK2 (Kyriakis and Avruch, 2001).  At this time, it seems 
that Raf has no other substrates apart from MEK1 and MEK2, and that MEK1/2 
have no other substrates than ERK1/2, which places Raf and MEK1/2 
exclusively in the ERK pathway (Pearson et al., 2001).  Following activation, 
ERK delivers signals to a variety of substrates, both cytosolic and nuclear 
(Krauss, 2003).  All MAPKs phosphorylate substrates on Ser and Thr residues 
which are followed by either a Pro or Gly residue.  
 
Phosphorylation by MEK causes ERK2 to dimerise.  This dimerization is 
brought on by a conformational change induced by phosphorylation that favours 
tight interactions between phosphorylated ERK2 proteins.  It is believed that this 
dimerization could promote nuclear localization of ERK2, which occurs by 
means of active transport (Cobb and Goldsmith, 2000).  Nuclear substrates 
include the transcription factor Elk-1, which is positively regulated by ERK.  Elk-
1 regulates the transcription of genes for proteins such as c-fos, which forms 
part of the transcription factor AP1 (activator protein 1) (Krauss, 2003).  Other 
important substrates include: 
• Cytosolic phospholipase A2 (Cpla2)  
• p90 ribosomal S6 kinases (p90RSK) 1-3  
• MAPK-interacting kinase (MNK) 1 and MNK2 
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• Mitogen- and stress-activated protein kinase (MSK) 
• Steroid receptor coactivator-1 (SRC-1) 
• c-Jun 
• c-Fos 
• Activating transcription factor 2 (ATF2) 
• Signal transducer and activator of transcription 3 (STAT3) (Pearson et 
al., 2001). 
2.3.3.2.  p38 MAPK 
As with ERK1/2, the p38 MAPK proteins are terminal kinases in a cascade 
consisting of three signalling modules that act in a sequential fashion.  
However, stimuli associated with activation of the p38 pathway are mostly 
stressful, such as heat and osmotic shock, UV irradiation, proinflammatory 
cytokines e.g. tumour necrosis factor (TNF) α and ischaemia (Hagemann and 
Blank, 2001; Matsukawa et al., 2004).   
 
There are at least four known isoforms of p38:  p38α, p38β, p38γ (a.k.a. ERK6 
or SAPK3), and p38δ (a.k.a. SAPK4) (Pearson et al., 2001). The α-isoform was 
the first to be purified and identified and is presently the best characterized 
isoform of p38 (Kyriakis and Avruch, 2001; Shi and Gaestel, 2002).  It was 
discovered as the target of a pyridinyl-imidazole drug (known as  SB203580) 
that inhibited TNFα transcription and was consequently named cytokine-
suppressive anti-inflammatory drug-binding protein (CSBP) (Lee et al., 1994; 
Cuenda et al., 1995).  p38α (CSBP) was also independently identified as a 
tyrosine phosphoprotein in cytokine-treated cell extracts (Han et al., 1994).  The 
other three isoforms were then identified by means of cloning strategies 
(Pearson et al., 2001).  Both p38α and also p38β are inhibited by the pyridinyl-
imidazole type compounds, but p38γ and p38δ are apparently insensitive to 
them (Kumar et al., 1997).  
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Figure 2.12 The ERK1/2 pathway and a number of substrates:  Pathway entry, steps 
in the cascade, and examples of ERK substrates (modified from 
Pearson et al., 2001 and Krauss, 2003).  Abbreviations:  EGF, 
epidermal growth factor; MAPK, mitogen-activated protein kinase; 
MAPKK, MAPK kinase; MAP3K, MAPKK kinase; MAP4K, MAP3K 
kinase; MEK, MAP/ERK kinase; MEKK, MEK kinase; ERK, extracellular 
regulated kinase; MSK, mitogen- and stress-activated protein kinase; 
p90RSK, 90 kDA-ribosomal S6 kinase; MNK, MAPK-interacting kinase.
MAP3K 
MAPKK 
MAPK 
Elk-1 p90RSKMSK1/2 MNK1/2 
Entry point into pathway
MAP4K 
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Gene-targeting (knockout) studies have shown that mice deficient in p38α die 
during embryonic development (Allen et al., 2000), due to defective 
angiogenesis of the placenta and decreased erythropoietin production (Kuida 
and Boucher, 2004).  On the other hand, knockouts of the β- and γ-isoforms do 
not cause any obvious phenotype (Kuida and Boucher, 2004), suggesting 
dispensable functions of these isoforms. 
 
In the p38 MAPK pathway (figure 2.13), the MAP3Ks at the top of the cascade 
are a complex and diverse group of proteins, with many members also 
signalling to JNK.  They can be subdivided as follows:  (1) MEKKs and (2) the 
thousand and one kinases (TAOs).  The mammalian MEKKs capable of 
delivering signals to p38 are MEKK2-4 (though little is known about their 
regulation), TGFβ-activated kinase 1 (TAK1), apoptosis signal-regulating kinase 
1 (ASK1), and tumour progression locus 2 (TPL2) (Kyriakis and Avruch, 2001).  
TAO1 and TAO2 of the TAO family are also distinctly specific activators of p38 
(Hagemann and Blank, 2001; Kyriakis and Avruch, 2001; Pearson et al., 2001). 
 
Downstream of the MAP3Ks, a group of MKKs are activated by means of 
Ser/Thr phosphorylation.  In the p38 MAPK pathway, these MKKs are MKK3 
(a.k.a. MEK3, SAPK-kinase 2, or SKK2)  and MKK6 (a.k.a. MEK6 and SKK3) , 
which are both highly selective for p38 (Derijard et al., 1995; Han et al., 1996; 
Hagemann and Blank, 2001).  Both MKK3 and MKK6 activate p38 by means of 
dual phosphorylation within a TGY-motif in the activation loop of subdomain VIII 
of p38’s kinase domain (Shi and Gaestel, 2002).  Although MKK3 prefentially 
activates the α- and β-isoforms, MKK6 activates all known isoform equally 
strongly (Kyriakis and Avruch, 2001).   
 
The downstream targets of p38 include a wide range of regulatory proteins 
including protein kinases, transcription factors, cPLA2, and the Na+/H+ 
exchanger NHE1.  These substrates act to fulfil the functions of the p38 
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pathway, which are currently known to be the regulation of gene transcription, 
posttranslational regulation of gene expression, cell cycle control (by means of 
p53), cell growth, differentiation, apoptosis, and cytoskeletal remodelling (Shi 
and Gaestel, 2002).  Precisely which substrates are responsible for the different 
effects of p38 activation, has not yet been fully elucidated, although targeted 
deletions of different substrates have been employed to at least partially 
address this.  A summary of known substrates and their roles in p38 signalling 
is given in table 4.  The p38 pathway specifically regulates the expression of the 
“early genes” c-fos, fosB, c-jun, junB, and junD in response to stress stimuli (Shi 
and Gaestel, 2002).  The expression of these genes is possibly mediated by 
means of the transcription factor Elk-1 (though results have been conflicting), 
which can also be regulated by ERK1/2 (Pearson et al., 2001; Shi and Gaestel, 
2002).   
 
The inactivation of p38 is also of physiological relevance and is mediated by 
dephosphorylation via specific MAPK phosphatases (MKPs).  The MKPs are 
dual specificity phosphatases acting on the super-family of MAPKs and are thus 
also involved in the inactivation of ERK, JNK, and other MAPKs.  Among the 
family of MKPs, at least MKP1, 5, and 7 specifically dephosphorylate p38 
MAPK (Pearson et al., 2001; Shi and Gaestel, 2002). 
2.3.3.3.  Akt 
Akt (a.k.a. protein kinase B or PKB) is a 57 kDa Ser/Thr kinase with similarities 
to both PKA and PKC (Coffer and Woodgett, 1991) and belongs to the “AGC” 
(for protein kinases A, G, and C) kinase super-family (Scheid and Woodgett, 
2003).  The Akt protein was discovered when two genes, Akt1 and Akt2, were 
identified as the human homologues of the viral oncogene v-akt (Staal, 1987; 
Bellacosa et al., 1991).  Presently, there are three known isoforms of Akt:  Akt1 
(a.k.a. PKBα), Akt2 (PKBβ), and Akt3 (PKBγ).  Although the isoforms are 
encoded by different genes and are expressed differentially (Akt2 and Akt3 are  
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Figure 2.13 The p38 MAPK pathway and selected substrates (modified from Kyriakis 
and Avruch, 2001 and Shi and Gaestel, 2002).  Abbreviations:  ASK1, 
apoptosis signal-regulating kinase 1; CK2, casein kinase 2; cPLA2, 
cytosolic phospholipase A2; MAPK, mitogen-activated protein kinase; 
MAPKK, MAPK kinase; MAP3K, MAPKK kinase; MAPKAPK, MAPK-
activated protein kinase; MEF2, myocyte enhancer factor 2; MEKK, 
MEK kinase; MKK, MAPK kinase; MNK, MAPK-interacting kinase; MSK, 
mitogen- and stress-activated protein kinase; NHE1, N+/H+ exchanger 1; 
PGC1, peroxisome proliferator-activated receptor (PPAR) co-activator 1; 
SAP1, stress-activated protein 1; TAK1, TGFβ-activated kinase 1; TAO, 
thousand and one kinase; TPL2, tumour progression locus 2; USF1, 
upstream transcription factor 1. 
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Table 2.4 Substrates of p38 MAPK and their roles, where known, in p38 MAPK 
related signalling (compiled from Shi and Gaestel, 2002 and Kyriakis 
and Avruch, 2001). Abbreviations:  C/EBPβ, CCAAT/enhancer-binding 
protein β; CHOP/GADD153, cAMP response element-binding protein-
homologous protein/growth arrest DNA damage 153; CK2, casein 
kinase 2; cPLA2, cytosolic phospholipase A2; MAPKAPK, MAPK-
activated protein kinase; MEF2, myocyte enhancer factor 2; MITF, 
microphthalmia transcription factor; MNK, MAPK-interacting kinase; 
MSK, mitogen- and stress-activated protein kinase; NHE1, N+/H+ 
exchanger 1; NFATp, nuclear factor of activated T cells; PGC1, PPAR 
co-activator 1; SAP1, stress-activated protein 1; STAT1, signal 
transducer and activator of transcription 1; USF1, upstream transcription 
factor 1. 
Substrate Function 
Type Name 
Apop- 
tosis 
Cell 
cycle 
control 
Growth 
and/or 
different-
tiation 
Gene  
expression/ 
transcript-
tion 
Trans- 
lational
 control 
Cyto- 
skeletal 
remodel-
ling 
Kinases MAPKAPK2, 3     ? ? 
 PRAK/ MAPKAPK5      ? 
 MNK1     ?  
 MSK1,2    ?   
 CK2   ?    
Transcription 
factors MEF2C, 2A   ? ?   
 SAP1 ?   ?   
 CHOP/GADD153   ? ?   
 C/EBPβ   ? ?   
 p53 ? ?  ?   
 STAT1    ?   
 MITF   ? ?   
 USF1    ?   
 NFATp    ?   
 CDX3   ? ?   
 MAX ?  ? ?   
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Substrate Function 
Type Name 
Apop- 
tosis 
Cell 
cycle 
control 
Growth 
and/or 
different-
tiation 
Gene  
expression/ 
transcript-
tion 
Trans- 
lational
 control 
Cyto- 
skeletal 
remodel-
ling 
 PGC1    ?   
Other cPLA2       
 Stathmin ?      
 NHE1       
 Cdc25B  ?     
 
 more tissue specific, whereas Akt1 is expressed broadly), they share more 
than 80% amino acid homology (Nicholson and Anderson, 2002).   
 
Structural examination of Akt has revealed an N-terminal pleckstrin homology 
(PH) domain (figure 2.14).  This was an important discovery, since the PH 
domain as a lipid-binding module is one of the major ways in which signal 
transduction molecules in the cytosol can be influenced by membrane-bound 
lipids (Lietzke et al., 2000; Vanhaesebroeck and Alessi, 2000).  Subsequent in 
vitro experiments confirmed that, just as with other signal transduction 
molecules with PH domains, Akt is capable of interaction with phosphoinositides 
via its PH domain (Klippel et al., 1997; Lietzke et al., 2000).  In fact, the binding 
 
 
Figure 2.14 Protein structure of Akt (Vanhaesebroeck and Alessi, 2000).  
Abbreviations:  HM, hydrophobic motif; PH, pleckstrin homology. 
 
of the phosphoinositides PI(3,4)P2  and PI(3,4,5)P3, to the PH domain of Akt is 
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a key step for activation, although it does not activate Akt directly (James et al., 
1996; Franke et al., 1997; King et al., 1997; Klippel et al., 1997).   
 
Phosphoinositides are the phosphorylated derivatives of phosphatidylinositol 
(PtdIns), a minor constituent of cell membranes (Vanhaesebroeck and Alessi, 
2000).  There are eight different phosphoinositides and their levels are 
regulated by PtdIns kinases that phosphorylate free –OH groups at the 3, 4, or 
5 position of the inositol ring in different combinations (Vanhaesebroeck and 
Alessi, 2000; Toker, 2002). The super-family of PtdIns 3 kinases (or PI3 
kinases), with its three different subclasses, phosphorylates the 3-OH position 
of the inositol ring of phosphoinositides to yield 3’-Pis. The subclasses of the 
PtdIns 3 kinase family differ by their phosphoinositide substrate preference.  For 
example, the Class I PtdIns 3 kinases utilise PtdIns, PI(4)P, and PI(4,5)P2 as 
substrates in vitro, to yield PI(3)P, PI(3,4)P2, and PI(3,4,5)P3, respectively 
(Krasilnikov, 2000; Toker, 2002).  However, the preferred substrate of PI3 
kinase in vivo seems to be PI(4,5)P2, which is converted to PI(3,4,5)P3. 
PI(3,4,5)P3 is then thought to be dephosphorylated by a 5’-inositol phosphatase 
to generate PI(3,4)P2 (Vanhaesebroeck and Alessi, 2000; Scheid et al., 2002). 
The first class of PtdIns 3 kinase is often simply referred to as phosphoinositide 
3 kinase (PI3 kinase), which reflects its substrate specificity more accurately 
than the super-family name, phosphatidylinositol 3 kinase (Krasilnikov, 2000).  
The nature of the lipid products generated by Class I PI3 kinase places PI3 
kinase upstream of Akt.  However, as previously mentioned, interaction 
between phosphoinositides and Akt does not amount to activation.  Instead, the 
activation of Akt is mediated by two distinct Ser/Thr phosphorylation events 
following phosphoinositide interaction at the plasma membrane. 
 
Phosphorylation of Akt occurs within its activation loop (at Thr308 of Akt1) and 
also within the hydrophobic motif (HM; at Ser473 of Akt1) (Scheid and 
Woodgett, 2003).  For Akt, the resting level of Thr308 phosphorylation is very 
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low, but increases rapidly upon stimulation.  The kinase responsible for 
activation loop phosphorylation is the constitutively activated phosphoinositide-
dependent kinase 1 (PDK1).  Like Akt, PDK1 possesses a PH domain that can 
bind PI(3,4)P2 and PI(3,4,5)P3.  According to studies on the interplay between 
PDK1 and Akt, the binding of phosphoinositides to the PH domain of Akt 
induces a favourable conformation of Akt which allows phosphorylation by 
PDK1.  Phosphoinositides may also serve an additional function towards Akt 
activation by promoting the co-localisation of Akt and PDK1 at the plasma 
membrane inner leaflet via PH domain interaction (Leevers et al., 1999).  
Besides Akt, PDK1 also phosphorylates the activation loops of numerous other 
AGC kinases (Scheid and Woodgett, 2003).   
 
Additional regulation of the activation of Akt is provided by an additional 
phosphorylation target in the HM (Ser473).  However, the mechanism of this 
phosphorylation is as yet not fully understood, and neither has the kinase 
responsible for it been identified with absolute certainty.  Although there are 
some reports suggestive of autophosphorylation (Toker and Newton, 2000) at 
the Ser473 site, others believe that a distinct kinase is at work.  Although it is 
not yet clear whether this is a novel protein or not, it is often referred to as 
PDK2, which implies a functional similarity to PDK1.  In fact, this is quite 
feasible, as it is known that both PI3 kinase activity as well as localisation of Akt 
to the plasma membrane is necessary for Ser473 phosphorylation (Scheid et 
al., 2002; Scheid et al., 2002), possibly implicating a dependence upon 
phosphoinositide interaction.  Numerous candidate kinases serving as PDK2 
have been suggested, including MAPKAPK2, integrin-linked kinase (ILK), p38 
MAPK, PKC, and DNA-PK (double-stranded DNA-dependent protein kinase) 
(Dong and Liu, 2005).   
 
Phosphorylation of both the Thr308 and Ser473 residues is essential for full 
activation of Akt (Alessi et al., 1996).  It has been speculated by some that 
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Thr308 phosphorylation causes a charge-induced change in the tertiary 
structure of Akt, which promotes a suitable conformation of the HM for Ser473 
phosphorylation (Scheid and Woodgett, 2003).  According to this hypothesis, 
phosphorylation at Thr308 occurs prior to Ser473 phosphorylation.  However, 
other hypotheses state that Ser473 phosphorylation takes place before the 
phosphorylation of Thr308 (Scheid and Woodgett, 2003).  Either way, research 
has shown that phosphorylation of these residues occurs independently from 
one another (Alessi et al., 1996). 
 
Other recent reports have even claimed that multiple Tyr phosphorylations are 
necessary for full Akt activation.  According to one such study, Tyr315 and 
Tyr326 in the catalytic domain are phosphorylated and assist in activation, since 
mutation of these residues abolished Akt’s enzymatic activity (Chen et al., 
2001).  Another study also identified Tyr474 as a site of phosphorylation, based 
on phosphopeptide mapping, and showed that phosphorylation of Ser473 and 
Tyr474 are mutually exclusive (Conus et al., 2002).  Interaction of Akt with 
Hsp90 is apparently also necessary to maintain activation (Brazil et al., 2002).  
 
Upon activation, Akt phosphorylates numerous substrates and thereby 
regulates important biological processes:  cellular survival, cell-cycle 
progression, growth, and metabolism (Shaw and Cantley, 2006).  These 
substrates are listed in figure 2.15.  Although it is not yet possible to link all 
substrates (partly because more substrates are bound to be discovered) with 
the different functions of Akt that they control, some are known.  For example, 
phosphorylation of Bad (Bcl-associated dimer), a pro-apoptotic member of the 
Bcl (B-cell lymphoma) 2 family, at Ser136 promotes its sequestration in the 
cytoplasm by 14-3-3 proteins. Its interaction with other Bcl2 proteins at the 
mitochondrial membrane, which leads to the release of cytochrome c and 
subsequently apoptosis, is thereby prevented (del Peso et al., 1997).  The 
phosphorylation of Bad is therefore associated with cell survival.  Another 
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survival mechanism controlled by Akt is the phosphorylation of members of the 
Forkhead family of transcription factors such as FKHR (a.k.a. FOXO).   
Phosphorylation by Akt inhibits its transcription of pro-apoptotic genes (such as 
Fas-ligand; FasL) by facilitating nuclear export towards the cytoplasm by 14-3-3 
proteins, inhibition of DNA binding, and disruption of cofactor interaction 
necessary for transcriptional activity (Burgering and Kops, 2002).  Other 
substrates associated with cellular survival include IκB kinase (IKK), caspase-9, 
ASK1, murine double minute 2 (MDM2), and cAMP-response element binding 
protein (CREB) (Nicholson and Anderson, 2002; Song et al., 2005).  However, 
Akt also plays a role in regulation of cell cycle progression by phosphorylation of 
the downstream targets glycogen synthase kinase 3 (GSK3), and p21.  Some 
substrates serve multiple purposes, such as MDM2, whose regulation is also 
implicated in cell cycle progression via p53 (Song et al., 2005).  Another dual 
purpose substrate is GSK3, which is inactivated by Akt to promote the storage 
of glucose as glycogen, in the presence of insulin.  Hereby, Akt is also 
implicated in the regulation of metabolism.  The glycolytic enzymes 6-
phosphofructo-2-kinase (PFK2) and hexokinase are also regulated by Akt.  
(Nicholson and Anderson, 2002; Shaw and Cantley, 2006).  In fact, the 
involvement of Akt in the regulation of glycolysis via mitochondrial hexokinase 
serves to couple the availability of glucose as a metabolic fuel to the inhibition 
of apoptosis (Gottlob et al., 2001).  The ways by which Akt mediates its effects 
are thus complex, as its substrates are mostly involved in more than one 
cellular process.  This possibly makes the Akt signalling pathway one of the 
most vital links between different events in the same cell. 
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Figure 2.15 The substrates of Akt (Nicholson and Anderson, 2002; Song et al., 
2005; Shaw and Cantley, 2006).  Abbreviations:  ASK1, apoptosis 
signal-regulating kinase 1; CREB, cAMP-response element binding 
protein; eNOS, endothelial nitric oxide synthase; GSK3, glycogen 
synthase kinase 3; IKK, IκB kinase; MDM2, murine double minute 2; 
PFK2, 6-phosphofructo-2-kinase. 
2.3.3.4.  p53 
The p53 gene is a tumour-suppressor with a decisive role in the prevention of 
human cancer.  Its protein product, known as p53, is a sequence-specific 
transcription factor (Oren, 2003).  The close correlation between tumourigenesis 
and mutations in the p53 gene has pressed researchers to investigate the 
structure and functions of this gene.  It is now known that p53 has a network of 
regulatory functions, both transcription-related and transcription independent, 
within the cell. 
 
The following are the central biological functions that have been ascribed to p53 
(Krauss, 2003): 
• It is an activator of the transcription of various genes that are involved in 
cell cycle control, apoptosis, angiogenesis, and the stress response. 
• It is part of a control mechanism that couples cell cycle progression to 
DNA integrity.  When the DNA is damaged, p53 halts the cell cycle at G1 
Akt 
 Bad  PFK2  IKK  caspase-9  MDM2  FKHR  GSK3 CREB  eNOS  ASK1  Raf  p21 
p53 p38 
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or at another phase whilst necessary maintenance is performed on the 
genetic material.   
• It is involved in the initiation of apoptosis. 
 
p53 is present in almost all tissues but is almost undetectable under normal 
circumstances due to its rapid degradation (Vousden, 2002; Krauss, 2003).  
This is because it resides in a latent state in the absence of cellular stressors.  
The few p53 molecules that do exist at this point are also relatively incapable of 
DNA binding and transcriptional activation.   However, p53 is rapidly activated 
upon stressful conditions.  The activation is marked by both a dramatic increase 
in the number of p53 molecules, and certain post-translational modifications 
including phosphorylation, methylation, ubiquitination, acetylation, and 
sumoylation (Krauss, 2003; Oren, 2003).  It appears that different types of 
damage induces different modification patterns via different enzymes, which 
transmit the nature of the stress signal to p53 (Harris and Levine, 2005).  The 
modifications appear to alter p53 in two ways:  firstly, its half-life is increased 
from 6-20 minutes to hours, which results in a 3–10-fold increase in 
concentration.  Secondly, its DNA binding ability is enhanced, and thereby its 
transcriptional activity (Harris and Levine, 2005).  There are generally three 
types of stressors that are able to induce p53 accumulation (Krauss, 2003; 
Harris and Levine, 2005): 
• Genotoxic stress (DNA damage) induced by e.g. γ-irradiation, UV, X-
rays, carcinogens, oxidative free radicals etc. 
• Oncogenic stress (the aberrant activation of growth factor-signalling 
cascades 
• Non-genotoxic stress e.g. hypoxia or ribonucleotide depletion 
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Figure 2.16 Overview of the effects of the p53 pathway, and the three main signals 
for its activation (Krauss, 2003). 
 
Activation of p53 in response to genotoxic stress (DNA damage) is almost 
always accompanied by the stabilisation of p53.  One of the major components 
regulating p53 stability is MDM2.  MDM2 regulates p53 in two ways:  by 
blocking its transcriptional activity (in the nucleus), and by shuttling it to the 
cytoplasm to be degraded.   
 
MDM2 forms a complex with p53 in the nucleus and thereby blocks its 
activation (Momand et al., 1992). The subcellular localisation of p53 is also 
influenced by interaction with MDM2, as nuclear export of p53 is enhanced by 
MDM2 (Mayo and Donner, 2002).  The amount of p53 available for transcription 
is thereby diminished (Krauss, 2003).  Nuclear export of p53 also underlies the 
degradation of the p53 protein.  MDM2 functions as an E3 ubiquitin ligase for 
p53, which mediates its ubiquitination and subsequent degradation in the 26S 
proteasome (Honda et al., 1997).  Interestingly, the MDM2 gene is a 
transcriptional target of p53, thus establishing an autoregulatory negative 
p53 
Cell cycle control DNA repair Apoptosis 
Differentiation 
DNA DAMAGE 
ACTIVATION OF 
ONCOGENES 
NON-GENOTOXIC 
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feedback loop in which p53 controls the expression of its own regulator (Haupt 
et al., 1997).  The fate of p53, as directed by MDM2, is directed by the level of 
MDM2 activity.  Whereas low MDM2 activity induces mono-ubiquitination and 
the nuclear export of p53, high MDM2 activity promotes poly-ubiquitination and 
p53 degradation (Li et al., 2003). 
 
In 2001, MDM2 was identified as a substrate of the Ser/Thr kinase Akt (Mayo 
and Donner, 2001; Zhou et al., 2001).  Akt phosphorylates MDM2 on Ser166 
and Ser186 in a domain containing a nuclear localisation motif (Mayo and 
Donner, 2002), thus facilitating its entry into the nucleus where it interacts with 
p53.   Phosphorylation of MDM2 is also associated with enhanced degradation 
of p53 in the proteasome.  The role of Akt-mediated MDM2 phosphorylation 
could be to suppress p53 activity during periods of proliferation in normal cells, 
and may also contribute to the ability of Akt to protect against p53-induced 
apoptosis, and thus enhanced cell survival (Vousden, 2002; Krauss, 2003).  
Apart from Akt, other signalling proteins such as Src and AP1 family members 
(e.g. c-Jun) are able to suppress p53 expression and also to inhibit the binding 
of p53 to target promoters.  These may also contribute in allowing normal 
cellular growth and proliferation and to reverse p53-mediated growth arrest 
following a stress response (Vousden, 2002).  Research has also shown that 
Akt can form a complex with the MDM2 protein, and that this interaction stands 
independent from the Akt-mediated phosphorylation of MDM2.  The significance 
of this association is not yet clear, although an in vitro role in the degradation of 
androgen receptors in prostate cells have been suggested (Brazil et al., 2002).   
 
Phosphorylation of p53 in the MDM2-binding region can impair the interaction 
between the two proteins.  Kinases such as chk (checkpoint kinase) 1 and 2, 
ATM (ataxia telangiectasia mutated) kinase, and ATR (ATM and Rad3-related) 
kinase are responsible for phosphorylation of these sites.  Other kinases such 
as JNK2 (in the face of non-genotoxic stress) have also been shown to 
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phosphorylate p53 and thereby regulate its stability.  ATM is also able to 
phosphorylate MDM2, although it occurs on a site distant from the p53- binding 
region (Maya et al., 2001).  Phosphorylation of the p53-binding region on MDM2 
by DNA-PK may also inhibit the interaction between p53 and MDM2 and inhibit 
the degradation of p53 (Mayo et al., 1997).  There are also many other 
mechanisms that allow for the stabilisation of p53, such as down-regulation of 
MDM2 expression, down-regulation of free ubiquitin levels, or competition 
between MDM2 and other proteins such as the TATA-binding protein-
associated factor (TAF) II31 and Strap that bind to the same region of p53 
(Vousden, 2002).   
 
Once p53 is activated, p53 tetramerises and initiates the transcription of genes 
that reflect the nature of the stress signal, the modifications to p53, and proteins 
associated with the p53 protein.  The activated p53 protein binds to a specific 
DNA sequence, termed the p53-responsive element.  The genes with this 
sequence initiate one of three programs that result in cell cycle arrest (G1 or G2 
blocks), cellular senescence, or apoptosis (Harris and Levine, 2005).  G1-arrest 
is largely mediated by p21, which inhibits cyclin E-cdk2.  G2-arrest, on the other 
hand, is partly mediated by the synthesis of 14-3-3σ, which sequesters the 
CDC25C phosphatase in the cytoplasm.  Very little is known concerning the 
genes regulated by p53 to bring about senescence.  The protein products of 
p53 regulated genes involved in apoptosis (bax, nox, puma) enhance the 
leakage of cytochrome c from the mitochondria into the cytoplasm, which sets 
off the intrinsic apoptotic programme (Miyashita and Reed, 1995; Schuler et al., 
2000).  There is also support for the notion that p53 can trigger apoptosis prior 
to transcription when it translocates to the mitochondria and interacts with pro-
apoptotic proteins such as the Fas death receptor and Bax (Bennett et al., 
1998; Erster et al., 2004). p53 also regulates genes of which the products 
initiate the extrinsic pathway (FasL, killer/DR receptor) (Harris and Levine, 
2005).  Other proteins from genes regulated by p53, including maspin and 
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thrombospondin, are secreted by cells into the extracellular matrix to 
communicate the stress response to neighbouring cells (Komarova et al., 1998).  
A list of target genes is given in table 5. 
2.3.3.5.  Apoptosis 
Apoptosis is the highly regulated process by which cells undergo programmed 
death and was first described in the nematode C. elegans.  It serves to 
eradicate undesired cells and is indispensable to the development and function 
of an organism (Cohen, 1997; Krauss, 2003).   
 
Apoptosis is characterized by a series of explicit changes in cellular morphology 
and biochemistry which include chromatin condensation, DNA cleavage (a.k.a. 
DNA laddering), fragmentation of the nucleus, compaction of cell organelles, 
cell shrinkage, blebbing, and the formation of membrane-bound cytoplasmic 
vesicles (apoptotic bodies) (Cohen, 1997; Krauss, 2003; Wang et al., 2005).  
Apoptotic cells eventually lose contact with the extracellular matrix and collapse, 
without ever releasing their contents into the environment.  The apoptotic debris 
is scavenged by neighbouring cells or phagocytes (macrophages and dendritic 
cells) without causing any inflammatory response.  This type of cell death is 
clearly discernible from the other major form of cell death termed necrosis, in 
which damaged cells lose cell membrane integrity and release their contents 
into the environment, leading to an inflammatory response.    Necrosis is also a 
passive process, whereas apoptosis requires energy (Gomperts et al., 2003; 
Vermeulen et al., 2005).   
 
The conditions under which apoptosis is initiated are diverse and include: 
• Tissue and organ homeostasis:  Increased cell numbers due to mitotic 
division in an organ or tissue are counter-balanced by apoptosis, which 
eliminates aged or defective cells.  The cell number in an organ or tissue 
is thereby kept within a suitable limit. 
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Table 2.5 Examples of genes regulated by the transcriptional activity of p53 (Yu et 
al., 1999; Krauss, 2003).  Abbreviations:  AIP, Apaf-1-interacting protein; 
COX, cyclooxygenase; GADD, Growth arrest and DNA damage; MDM2, 
murine double minute 2; NOS, Nitric oxide synthase; TFIIH, TATA-
binding protein-associated factor IIH. 
Target gene Function 
14-3-3σ Cell cycle arrest 
AIP1 Apoptosis 
Bax Apoptosis 
Bcl2 Apoptosis 
COX2 Stress response 
Cyclin A Cell cycle arrest 
DR5/Killer Apoptosis 
Fas Apoptosis 
GADD45 Cell cycle arrest 
Maspin Communication with neighbouring cells 
MDM2 Negative feedback control 
NOS1 Stress response 
Noxa Apoptosis 
p21 Cell cycle arrest 
Puma Apoptosis 
Rad51 DNA repair 
TFIIH p62 subunit DNA repair 
Thrombospodin Angiogenesis 
XPB and XPD DNA repair 
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• Development and differentiation:  Especially during embryonic 
development, cells that are no longer needed are eliminated by 
apoptosis. 
• Immunity:  T-lymphocytes eliminate target cells (e.g. virally-infected 
cells) by means of apoptosis.  Also, autoreactive T- or B-lymphocytes 
undergo apoptotic death.   
• Cell damage:  Damaged cells can be destroyed by apoptosis.  In the 
case of cells with DNA damage or viral infection, apoptosis is especially 
important to eliminate these cells before they can accumulate mutations 
and become neoplastic (Krauss, 2003; Vermeulen et al., 2005). 
 
Central to the apoptotic programme is the family of proteolytic enzymes known 
as caspases (a.k.a. cysteine aspartate-specific proteases, because they contain 
a Cys residue in their catalytic site and cleave substrates at specific peptide 
sequences containing an Asp residue) (Gomperts et al., 2003).  When the first 
caspase enzyme was discovered, it was named the interleukin-1β-converting 
enzyme (ICE).  Enzymes similar to ICE were later discovered, and found to be 
involved in apoptosis.  A collective name was thereafter assigned to this group 
of enzymes, now known as caspases, and today ICE is known as caspase-1 
(Cohen, 1997).  To date, fourteen members of the caspase family have been 
identified and cloned in mice, of which seven are involved in apoptosis 
(Vermeulen et al., 2005).  Of these, all but caspases-11 and -13 have human 
counterparts (Ho and Hawkins, 2005). 
 
Caspases share similarities in sequence, structure, size (30–50 kDa) and 
substrate specificity.  They are all expressed as single-chain, inactive pro-
enzymes with three domains:  an N-terminal pro-domain, a large subunit, and a 
small subunit.  Inactive caspases undergo conformational changes and are 
cleaved at their internal proteolytic site to yield the active form of the enzyme 
(Ho and Hawkins, 2005; Wang et al., 2005).   
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The two caspase sub-families, initiator (caspase-2, -8, -9, -10, and -12) and 
effector caspases (caspase-3, -6, -7, and -14), are involved in the initiation and 
execution of apoptosis, respectively (Ho and Hawkins, 2005).  Initiator caspases 
have long N-terminal prodomains that contain recognisable protein-protein 
interaction motifs (Wang et al., 2005).  These motifs enable initiator caspases to 
cleave and thereby activate themselves following dimerisation.  The effector 
caspases, on the other hand, possess short or no prodomains, and are cleaved 
and activated by the initiator caspases (Cohen, 1997; Gomperts et al., 2003). 
The initiator caspases-8 and -10 contain a death effector domain (DED) within 
their prodomain, which is involved in interactions with adaptor molecules, which 
will be discussed later.  Caspases-2 and -9 contain a caspase-associated 
recruitment domain (CARD) which is also involved in binding with adaptor 
molecules, but also in the activation of downstream effector caspases (Ho and 
Hawkins, 2005; Vermeulen et al., 2005).   
 
It is believed that the activation of initiator caspases is suppressed under normal 
conditions through binding of inhibitory proteins that inhibit caspase 
dimerisation and subsequent activation.  Another mechanism for the inhibition 
of initiator caspases is the binding of Bcl2 to Apaf (apoptotic protease activating 
factor), an adaptor molecule for initiator procaspase dimerisation (Gomperts et 
al., 2003).   
 
Usually, activated initiator caspases will activate downstream effector caspases 
in a cascade fashion (Slee et al., 1999).  Effector enzymes, the true 
executioners of the apoptotic programme, will then cleave their substrates, such 
as poly(ADP-ribose) polymerase (PARP), lamins (the major structural proteins 
of the nuclear envelope), DNA-PK, inhibitor of caspase-activated DNAase 
(ICAD), actin, and a host of others.  The cleavage of these substrates would 
ultimately result in the stereotypical morphological changes associated with 
apoptosis (Vermeulen et al., 2005; Wang et al., 2005).  PARP is possibly the 
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best characterised proteolytic caspase substrate.  Under normal conditions, 
PARP plays an important role in DNA repair, a process which can easily deplete 
stores of nicotinamide adenine dinucleotide (NAD+) and adenosine triphosphate 
(ATP).  It has been suggested that the cleavage of PARP serves to conserve 
NAD+ and ATP to be utilised for the execution of apoptosis (Cohen, 1997; 
Vermeulen et al., 2005).  The caspase-mediated cleavage of signalling proteins 
such as Akt and Raf as well as pro-apoptotic proteins Bid (Bcl2-interacting 
death agonist) and Bax (Bcl-associated partner containing six exons) and 
certain transcription factors have also been reported (Vermeulen et al., 2005). 
 
Overall, the functions of the caspases in apoptosis can be summarised as 
follows (Wang et al., 2005):   
• to arrest cell cycle progression 
• to inactivate the DNA repair and replication systems 
• to inactivate the inhibitor of apoptosis proteins (IAPs) 
• to dismantle the cytoskeleton  
 
To date, four major pathways leading to the activation of caspases have been 
suggested (Wang et al., 2005).  Of these, the two best characterised pathways 
are the so-called death receptor-dependent (extrinsic) and mitochondrial 
(intrinsic) pathways. Other pathways are the endoplastic reticulum (ER)-
mediated and the granzyme B-mediated pathways.  
2.3.3.5.a)  The death receptor-dependent pathway of apoptosis 
Death receptors (DRs) belong to the TNF receptor (TNFR) superfamily.  They 
include Fas, TNFR1, TNFR2, and DR3-6.  These transmembrane receptors are 
characterised by the presence of a cytoplasmic death domain.  Interactions 
between the death domains of these receptors lead to the recruitment of 
adaptor proteins and also initiator procaspases (Ho and Hawkins, 2005). 
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In the Fas-mediated pathway, Fas is activated by its ligand FasL in order to 
initiate the caspase cascade.  In the absence of FasL, inactive complexes of 
Fas are formed by the pre-ligand-binding assembly domains of the receptors.  
Interaction with FasL causes the reassembly of these complexes and allows the 
formation of a death-inducing signalling complex (DISC).  DISC contains the 
adaptor protein Fas-associated death domain (FADD) and also procaspases-8 
and -10.  The FasL-induced clustering of Fas, FADD, and caspase-8 or -10 
within the DISC brings the caspases in close proximity, resulting in mutual 
cleavage and activation.  The activated caspases are then released from the 
cluster.  Activated caspase-8 will in turn directly activate effector caspases to 
induce apoptosis (Cho and Choi, 2002; Wajant, 2002).   
 
The caspase-8–activating capacity of the DISC is mainly regulated by FADD-
like ICE (FLICE)-like inhibitory protein (FLIP).  FLIP can be integrated into the 
DISC of death receptors (such as Fas or TNF receptors), thereby inhibiting 
DISC-mediated recruitment, processing and release of active caspase-8.  In 
addition, Fas-mediated apoptosis is controlled by numerous regulators of the 
mitochondrial pathway, such as members of the Bcl2 (Wajant, 2002). 
 
Besides Fas, other DRs activate initiator caspases in a similar fashion.  The 
binding of the extracellular signalling protein TNFα to its receptor TNFR1 leads 
to the formation of TNFR1 trimers and also recruits adaptor molecules TNFR-
associated death domain protein (TRADD), receptor interacting protein (RIP) 1, 
and TNFR-associated factor 2 (TRAF2).  During receptor endocytosis the 
receptor cluster is modified, promoting the dissociation of TRADD and the other 
adaptor molecules (Ho and Hawkins, 2005).  The death domain of TRADD then 
interacts with the death domain of FADD, which recruits procaspase-8 and 
causes its autoproteolytic activation.  Active caspase-8 then activates 
downstream effector caspases (Vermeulen et al., 2005). 
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2.3.3.5.b)  The mitochondrial pathway of apoptosis 
The mitochondrial pathway is activated from within the cell and does not involve 
any extracellular mediators.  In this pathway, apoptotic signals are relayed by 
the pro-apoptotic proteins of the Bcl2 family, such as Bax and Bak (Bcl2 
homologous antagonist/killer).  Normally, these pro-apoptotic proteins are 
regulated by the anti-apoptotic Bcl2/BclXL family members, with which they form 
heterodimers.  However, upon receipt of the appropriate signals, these pro-
apoptotic proteins translocate from the cytoplasm to the outer membrane of the 
mitochondria where the prompt it to release different proteins from the 
intermembranous space between the mitochondrial membranes.  These 
proteins include cytochrome c, apoptosis-inducing factor (AIF), endonuclease 
G, and second mitochondria-derived activator of caspases/direct IAP-binding 
protein with low PI (SMAC/Diablo) (Krauss, 2003).  Although the mechanism of 
the release of these proteins has not yet been completely elucidated, it is likely 
that the mitochondrial permeability transition pore (PTP) at the contact site 
between the inner and outer mitochondrial membranes plays a fundamental 
role (Vermeulen et al., 2005).  Of these mitochondrial proteins, cytochrome c is 
arguably the most important, because it promotes the assembly of the 
apoptosome, which is also known as the mitochondrial DISC (Krauss, 2003).  
The apoptosome is a multiprotein complex, consisting of seven Apaf-1 
molecules in association with cytochrome C and ATP, surrounding seven 
procaspase-9 molecules in its core (Acehan et al., 2002).  It is believed that 
Apaf-1 plays a structural role in the apoptosome, enhancing allosteric 
conformation of procaspase-9 rather than driving its activation by 
autoproteolysis.  In accordance with this hypothesis, it has also been shown 
that the cleavage of procaspase-3 is in fact mediated by the procaspase-
9/Apaf-1 complex (Rodriguez and Lazebnik, 1999; Krauss, 2003).   
2.3.3.5.c)  The ER-mediated pathway 
In this pathway, procaspase-12, specifically localised on the cytoplasmic face of 
the ER, is thought to be an initiator caspase.  Several possible mechanisms for 
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the cleavage of procaspase-12 have been postulated, such as m-calpain-
mediated processing or by association with Apaf-1. Downstream of caspase-12, 
JNK is then translocated to the mitochondria, where it indirectly stimulates 
cytochrome c release (Wang et al., 2005). 
2.3.3.5.d)  The granzyme B-mediated pathway 
This pathway is involved in the cytotoxicity of natural killer (NK) cells and 
cytotoxic T cells.  Granzyme B can induce caspase-dependent apoptosis in 
target cells by initiating caspase cleavage, although it cannot fully activate 
caspase-3.  Other mediators such as cytochrome C, SMAC/Diablo, and Bid are 
also involved (Wang et al., 2005).  
2.4.  PURPOSE OF RESEARCH 
It is clear from several in vivo studies that the incidence and progression of 
cancer can be influenced by certain fatty acids.  In vitro, certain fatty acids have 
also been shown to be cytotoxic, whilst normal cells remain unaffected.  
However, the underlying mechanisms by which fatty acids exert these 
differential effects have not yet been elucidated in cancer cells in vitro.  
Therefore, the objective of the present study was to uncover some of these 
mechanisms, especially those related to signal transduction. 
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CHAPTER 3 
MATERIALS AND METHODS 
3.1.  MATERIALS 
NCM460 cells were purchased from InCell Corporation (San Antonia, Texas, 
USA).  CaCo2 cells, Eagle’s minimum essential medium (MEM), FCS, trypsin 
and penicillin/streptomycin were obtained from Highveld Biological (Lyndhurst, 
RSA).  Cell culture plastics were purchased from Greiner Bio-one 
(Frickenhausen, Germany).  Arachidonic acid (n-6, 20:4; AA), palmitic acid 
(16:0; PMA), oleic acid (n-9, 18:1; OA), docosahexaenoic acid (n-3, 22:6; DHA), 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and 
protease inhibitors were obtained from Sigma Chemicals (St. Louis, Missouri, 
USA).   
 
Silica gel plates and dimethyl sulfoxide (DMSO) were purchased from Merck 
(Darmstadt, Germany).  Megabore DB225 chromatography columns were 
obtained from J&W Scientific (Folsom, California, USA).  Fatty acid methyl ester 
standards were obtained from Nu-Chek-Prep Inc. (Elysian, Minnesota, USA).   
 
2’-Amino-3’-methoxyflavone (PD 98059; MEK inhibitor), and water-soluble 4-(4-
fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole, HCl (SB 
203580; p38 MAPK inhibitor) were obtained from Calbiochem (La Jolla, 
California, USA).  Wortmannin (PI3 kinase inhibitor), rabbit polyclonal 
antibodies, rabbit monoclonal antibodies, and the SignalSilence® p38 MAPK 
short interfering RNA (siRNA) kit (which includes transfection reagent and p38 
MAPK siRNA) were purchased from Cell Signaling Technology (Beverly, 
Massachusetts, USA).  All electrophoresis equipment was from Bio-Rad 
(Herculus, California, USA).  Polyvinylidene fluoride (PVDF; 0.45 μm) 
membranes for Western blots were obtained from Millipore (Bedford, 
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Massachusetts, USA).  Prestained protein markers were obtained from 
PeQLAB Biotechnologie (Erlangen, Germany) and Bio-Rad (Herculus, 
California, USA).  The chemiluminescence system (ECL Plus and ECL), 
autoradiography film as well as anti-rabbit horseradish peroxidase (HRP)-linked 
secondary antibody (from donkey) were obtained from Amersham Biosciences 
(Arlington Heights, Illinois, USA).  Other standard chemicals were obtained from 
commercial sources.   
3.2.  METHODS 
3.2.1.   Preparation of fatty acid stock solutions 
Fatty acid stock solutions (100 mM) were prepared in 99% ethanol.  The stock 
solutions were stored under nitrogen gas in opaque microcentrifuge tubes at  
-80°C to prevent their degradation.   
 3.2.2.  Cell culture 
NCM460 and CaCo2 cells were maintained at 37°C in a humidified 5% CO2 
atmosphere in MEM supplemented with 10% FCS and 1% 
penicillin/streptomycin (standard medium).  Cells were routinely subcultured 
before reaching confluency and maintained for up to 20 passages.  Cell 
numbers were determined using a haemocytometer following trypsinization.  
For MTT assays, CaCo2 and NCM460 cells were seeded in 35 mm Petri dishes 
(120 000 cells/dish and 350 000 cells/dish, respectively).  For total phospholipid 
analysis and Western blots, CaCo2 cells were seeded in 100 mm (360 000 
cells/dish) and 60 mm Petri dishes (240 000 cells/dish), respectively.  CaCo2 
cells were seeded in six-well plates for RNAi experiments (120 000 cells/well).   
 
Prior to fatty acid treatment, standard media were replaced by MEM 
supplemented with 2% FCS and 1% penicillin/streptomycin (serum-poor 
medium).  Working fatty acid solutions were also prepared in serum-poor 
medium (1 mM).  Cells were treated with the working fatty acid solutions at a 
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final concentration of 10 μM.  Cells treated with the ethanol vehicle only were 
used as controls.   
 3.2.3.  Treatment of cells with kinase inhibitors 
Stock solutions of kinase inhibitors were prepared in DMSO (wortmannin and 
PD 98059) or in water (SB 203580) and stored at -20°C.  CaCo2 cells were 
treated with the inhibitors wortmannin (500 nM), PD 98059 (10 μM), or SB 
203580 (10 μM) in standard medium for 30 min.  Media were then replaced with 
serum-poor medium, treated with DHA for 30 min, and prepared for Western 
blot analysis.   
3.2.4.  Cell proliferation assessment 
The MTT assay was employed to determine the effect of fatty acids and the 
different vehicles on proliferation (or cell functionality).  The MTT assay is a 
colorimetric technique based on the ability of the mitochondria of living cells to 
convert the tetrazolium compound, MTT, into blue formazan crystals (Campling 
et al., 1988).  Following treatment with fatty acids or vehicle for 48 h, cells were 
washed with phosphate buffered-saline (PBS) and incubated with the MTT 
(0.2% in PBS) for 2 h at 37°C.  Then the crystals formed were dissolved in 
0.002% Triton X-100 in 1% HCl-isopropanol.  Each sample was assayed 
spectrophotometrically (540 nm).  Proliferation of samples is expressed relative 
to control values (100%). 
 3.2.5. Determination of fatty acid composition of phospholipids 
To examine the incorporation of supplemented fatty acids in the CaCo2 cells’ 
phospholipid fraction after a 48 h incubation period, cells were rinsed twice with 
ice cold saline (0.9% NaCl w/v), and scraped into 500 µl of cold saline.  The 
lysates were sonicated for short bursts and centrifuged at 4°C for 15 minutes at 
6 000 g.  Phospholipids extracts were prepared in chloroform/methanol (2:1, 
v/v) according to the method of Folch and colleagues (Folch et al., 1957).  All 
extraction solvents contained butylated hydroxytoluene (BHT; 0.01% v/v) as an 
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antioxidant.  Heptadecanoic acid (C17:0) was used as internal standard to 
quantify the individual fatty acids.  Neutral lipids were separated from 
phospholipids by thin layer chromatography (TLC) on pre-coated 10x10 cm 
silica gel plates without a fluorescent indicator using the solvent system 
petroleum benzene (boiling range 40-60°C)/diethyl ether (peroxide free)/acetic 
acid (90:30:1 v/v).  Lipid bands were visualized with longwave ultraviolet light 
after spraying the plates with chloroform/methanol (1:1 v/v) containing 2,5-
bis(5’-tertbutylbenzoxazolyl-(2’)thiophene (BBOT; 10 mg/100ml).  The total 
phospholipids band was scraped off and its fatty acid composition was analysed 
as described previously (van Jaarsveld et al., 2000).  Lipids were 
transmethylated using 5% H2SO4/methanol at 70°C for 2h.  After cooling, the 
resulting fatty acid methyl esters (FAMEs) were extracted with 1 ml water and 2 
ml n-hexane.  The top hexane layer was evaporated to dryness, redissolved in 
CS2 and analysed by gas-liquid chromatography (GLC) using a Varian 3300 
Gas Chromatograph on 30 m fused silica DB225 columns of 0.53 mm internal 
diameter.  Gas flow rates were:  hydrogen 25 ml/min, air 250 ml/min, and 
hydrogen (carrier gas), 5-8 ml/min.  Temperature programming was linear at 
4°C/min: initial temperature 160°C, final temperature 220°C, injector 
temperature 240°C, and detector temperature 250°C.  The FAMEs were 
identified by comparison of the retention times to those of a standard FAME 
mixture. 
 3.2.6.  siRNA knockdown of p38 MAPK  
CaCo2 cells were plated in six-well plates in standard medium.  The following 
day, siRNA was freshly prepared in serum-free medium containing the 
transfection agent.  The cells were then transfected with 15 nM siRNA in 
standard medium and agitated vigorously to disperse siRNA evenly.  After 24h, 
the siRNA-containing medium was taken off and cells were treated with DHA in 
serum-poor medium for 30 min.  Cells were then lysed, and prepared for 
Western blot analysis. 
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3.2.7.  Western blot analysis 
Cells were washed twice with icy cold PBS and lysed on ice with 120 µl 
modified radioimmunoprecipitation assay (Ripa) buffer (50 mM Tris-HCl, pH 7.4, 
1% Nonidet P40 substitute, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM 
ethylenediaminetetraacetic acid [EDTA], 1 mM phenylmethylsulphonylfluoride 
[PMSF], 1 μg/ml leupeptin, 4 μg/ml soybean trypsin inhibitor [SBTI], 1 mM 
benzamidine, 1 mM Na3VO4, and 1 mM NaF).  The lysates were sonicated for 
short bursts and centrifuged at 4°C for 15 min at 6000g.  Protein content of the 
supernatants was determined by the method according to Bradford (Bradford, 
1976), using bovine serum albumin (BSA) as a standard.  The supernatants 
were diluted 1:1 with sample buffer (59.5 mM Tris-HCl pH 6.8, 23.8% glycerol, 
5% β-mercaptoethanol, 1.9% sodium dodecyl sulphate [SDS], 0.05% 
bromophenol blue) and heated to 95-100°C for 4 min prior to electrophoresis.  
Proteins (20 µg per lane) were resolved on 7, 10, or 12% SDS-polyacrylamide 
gels at 200 V for 50 minutes.  Resolved proteins were then transferred onto 
PVDF membranes in a Bio-Rad Trans-Blot SD semi-dry transfer cell (15V, 1 h).  
Residual binding sites on the membrane were blocked in 5% non-fat milk in 
TBS-T (1 x tris-buffered saline [TBS], pH 6.8, 0.1% Tween-20) for 1 h.  Blots 
were then incubated (overnight at 2-4°C) with anti-rabbit primary antibodies 
(1:1000) in TBST (for polyclonals) or 5% milk (for monoclonals).  Blots were 
washed in TBS-T (3 x 5 min) and incubated with the HRP-conjugated 
secondary antibody (1:8000) in TBS-T at room temperature for 1 – 2 h and 
washed (3 x 15 min).  Bands were finally visualized with ECL or ECL Plus.  
Densitometric data of autoradiographs were determined with the Un-Scan-It 
software package (version 5.1, Silk Scientific Corporation, Orem, Utah, USA).   
3.2.8.  Statistical analysis 
All experiments were carried out in triplicate, except where stated otherwise.  
Results were analysed by one-way analysis of variance (ANOVA) for 
comparison of multiple groups, followed by a post-hoc test with the Bonferroni 
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correction using Prism version 2.01 (GraphPad Software Inc, San Diego, 
California, USA).  Unless specified otherwise, data are presented as mean ± 
standard error of the mean (SEM).   
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CHAPTER 4 
RESULTS I 
 
In this chapter, results are shown from the experiments in which four different 
fatty acids were tested on NCM460 and CaCo2 cells.  The effects of these fatty 
acids on proliferation of the cells were assessed by MTT assays.  The 
incorporation of these fatty acids into the phospholipid fraction of total lipids was 
also assessed in CaCo2 cells by means of GLC. 
4.1  THE EFFECTS OF DIFFERENT FATTY ACIDS ON 
PROLIFERATION 
NCM460 and CaCo2 cells were cultured to 70-80% confluency and then 
supplemented for 48h with AA, PMA, OA, or DHA (10 µM) in serum-poor 
medium.  MTT assays were performed to evaluate the effects of the fatty acids 
on proliferation (or cell functionality; figure 4.1).  DHA and PMA significantly 
increased the viability of NCM460 cells compared with control cells (156 ± 5%, 
p<0.001 for DHA and 140 ± 7% for PMA). Furthermore, DHA caused a 
significant decrease in the functionality of the CaCo2 cells compared with the 
control cells (89 ± 0.577%, p<0.01). 
4.2.  THE FATTY ACID COMPOSITION OF TOTAL 
PHOSPHOLIPIDS OF CACO2 CELLS 
SUPPLEMENTED WITH DIFFERENT FATTY ACIDS 
The membrane phospholipids of CaCo2 cells supplemented for 48h with 
different fatty acids were isolated and analysed.  Fatty acid content was 
determined as percentages of total phospholipids, which when combined yields 
100%.  The relative fatty acid composition of total phospholipids in the 
experimental groups is shown in table 4.1.  In figure 4.2, the total saturated, 
monounsaturated, and polyunsaturated fatty acids as percentages of the total 
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phospholipids in experimental groups are summarised.   
 
Regarding the mean profiles of individual fatty acids, all experimental groups 
except the PMA group had significantly altered fatty acid content compared to 
the control.  As could be expected, AA, OA, and DHA supplementation resulted 
in a significantly higher AA (mean difference [MD] 2.46%, p<0.05), OA (MD 
3.62%, p<0.001), and DHA (MD 1.09%, p<0.01) content in those groups, 
compared to controls, respectively.  However, AA supplementation also resulted 
in a decreased content of OA (MD 2.76%, p<0.01) together with an increased 
content of 22:4 n-6 (MD 1.07%, p<0.001).  Compared with the control, AA 
supplementation resulted in an overall lower total MUFA index (MD 4.41%; 
p<0.05) in those cells.  The AA group also had a significantly lower total MUFA 
index in comparison with the PMA (MD 5.47%; p<0.01) and OA (MD 7.27%; 
p<0.001) groups, but a higher total SFA index compared with the OA group (MD 
3.78%; p<0.05).  Supplementation with OA, on the other hand, decreased the 
palmitoleic acid (16:1 n-7; MD 1.26%, p<0.05) content of that group, whilst also 
resulting in an increased content of eicosenoic acid (20:1 n-9; 0.33%, p<0.05).  
However, the total MUFA index of the OA group was significantly higher than 
that of the DHA group (MD 5.07%, p<0.01), even though it did not differ 
significantly from the control or any other group.  DHA supplementation did not 
significantly modulate the phospholipid content of any fatty acid other than itself 
in that group.  No further statistically significant differences were observed in 
other groups with regard to total SFA, MUFA, or PUFA indices. 
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Figure 4.1 Effect of supplementation with different fatty acids on proliferation of 
NCM460 and CaCo2 cells.  Cells were cultured in standard medium and 
supplemented with fatty acids (10 µM) in serum-poor medium for 48h.  
The MTT assay was performed as described in the Methods section.  
Values are expressed as percentages of controls (100%).  
Abbreviations:  AA, arachidonic acid; DHA, docosahexaenoic acid; OA, 
oleic acid; PMA, palmitic acid;  * p<0.05 versus NCM460 control; # 
p<0.001 versus NCM460 control; ? p<0.01 versus CaCo2 control.  
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Table 4.1 Fatty acid composition of total phospholipids of CaCo2 cells 
supplemented with various fatty aids.  Cells were supplemented with 
different fatty acids (10 µM) for 48h in serum-poor medium.  Total 
phospholipids were isolated and their fatty acid profiles determined as 
outlined in the Methods section.  Abbreviations:  AA, arachidonic acid; 
DHA, docosahexaenoic acid; OA, oleic acid; PMA, palmitic acid.   
Fatty acid Ctrl AA PMA OA DHA 
ANOVA 
(vs. Ctrl) 
14:0 1.54±0.24 1.76±0.09 1.47±0.51 1.20±0.39 1.70±0.17 ns 
16:0 22.76±0.37 24.02±0.21 23.00±0.34 21.10±1.26 23.16±0.31 ns 
18:0 11.60±0.17 11.93±0.19 11.60±0.13 11.68±0.43 12.13±0.31 ns 
20:0 0.21±0.00 0.20±0.00 0.22±0.01 0.21±0.01 0.22±0.01 ns 
24:0 0.52±0.04 0.46±0.01 0.53±0.03 0.42±0.01 0.47±0.02 ns 
16:1 n-7 4.79±0.23 3.78±0.12 4.55±0.05 3.53±0.47* 4.39±0.05 p<0.05 
18:1 n-7 15.62±0.61 14.08±0.11 16.48±0.10 15.24±0.24 14.53±1.14 ns 
18:1 n-9 23.78±0.15 21.02±0.09* 24.20±0.23 27.40±0.48# 22.87±0.47 
* p<0.01; 
# p<0.001 
20:1 n-9 1.18±0.03 1.06±0.06 1.21±0.03 1.51±0.06* 1.02±0.07 p<0.05 
24:1 n-9 0.34±0.34 1.38±0.10 0.34±0.34 0.91±0.47 0.71±0.71 ns 
18:2 n-6 3.77±0.23 3.44±0.06 3.51±0.12 3.46±0.13 3.88±0.15 ns 
20:2 n-6 0.41±0.02 0.39±0.01 0.41±0.01 0.47±0.04 0.42±0.01 ns 
18:3 n-6 0.50±0.04 0.48±0.02 0.53±0.04 0.48±0.05 0.50±0.02 ns 
20:3 n-6 1.04±0.04 1.02±0.01 1.02±0.02 0.98±0.02 1.05±0.06 ns 
20:4 n-6 6.88±0.58 9.35±0.14* 6.19±0.14 6.80±0.45 6.95±0.49 p<0.05 
22:4 n-6 0.93±0.09 2.00±0.10* 0.84±0.04 0.90±0.04 0.86±0.06 p<0.001 
20:5 n-3 0.20±0.02 0.16±0.01 0.18±0.01 0.16±0.00 0.23±0.03 ns 
22:5 n-3 1.13±0.10 1.00±0.04 1.20±0.17 1.04±0.05 1.08±0.07 ns 
22:5 n-6 0.14±0.02 0.14±0.03 0.12±0.01 0.13±0.01 0.13±0.01 ns 
22:6 n-3 2.31±0.20 2.05±0.07 2.07±0.08 2.12±0.11 3.40±0.25* p<0.01 
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Figure 4.2 Comparison of the relative mean percentages of total saturated, 
monounsaturated, and polyunsaturated fatty acids in total phospholipids 
of CaCo2 cells treated with different fatty acids.  Cells were cultured, 
supplemented with fatty acids (10 μM) for 48h and total phospholipids 
were analysed as outlined in the Methods section.  Abbreviations:  AA, 
arachidonic acid; DHA, docosahexaenoic acid; OA, oleic acid; PMA, 
palmitic acid;  * p<0.05; # p<0.01; ? p<0.001. 
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CHAPTER 5 
RESULTS II 
 
The results presented in this chapter involve the use of DHA only.  In light of the 
results shown in the preceding chapter, DHA was selected as the most suitable 
fatty acid to use in the subsequent experiments.   
5.1.  THE CYTOTOXICITY OF VARIOUS 
CONCENTRATIONS OF DHA IN NORMAL AND 
CANCER CELLS 
To confirm the effect of DHA, different concentrations were tested on both cell 
lines.  In CaCo2 cells, decreased proliferation was observed with increased 
concentrations of DHA (figure 5.1), although the dose efficacy can only be 
evaluated in conjunction with its effect on NCM460 cells.  Low and medium 
concentrations (5-50 µM) seem to be most efficient, because NCM460 
functionality is not compromised.  The high dose (100 µM) was toxic to both cell 
lines.   
5.2.  SHORT- AND LONG-TERM DHA 
SUPPLEMENTATION INFLUENCES 
PHOSPHORYLATION OF VARIOUS SIGNALLING 
MOLECULES 
The short-term as well as long-term effects of DHA on CaCo2 cells were 
assessed by Western blotting.  CaCo2 cells were cultured until 70-80% 
confluence and then supplemented with DHA (10 µM) in serum-poor medium 
for varying time periods ranging from 2 min – 6h (short-term treatment) and 
from 6h – 48h (long-term treatment).  The phosphorylation status of Akt (Ser473 
and Thr308), ERK (Thr202/Tyr204), p38 (Thr180/Tyr182), and p53 (Ser15) was 
then measured with phospho-specific antibodies.  Changes in total protein level 
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were also measured with antibodies that recognise the proteins of interest 
regardless of their phosphorylation status.   
5.2.1.  Phosphorylation of Akt at Ser473 
Short-term DHA supplementation induced phosphorylation of Akt at Ser473 as 
early as 2 minutes following treatment (figure 5.2A).  The increased intensity of 
phosphorylation continued up to 10 min after addition of the fatty acid, but 
declined thereafter to its basal intensity.  Although statistically significant 
differences between the different time points could not be seen, this trend was 
well established in three successive experiments.  Long-term DHA 
supplementation seemed to have a strong suppressive effect on Ser473 
phosphorylation which continued up to 48h (figure 5.2B).  Once again, this trend 
was well established despite the lack of statistical significance.  Total protein 
levels of Akt did not change (figure 5.2B). 
5.2.2.  Phosphorylation of Akt at Thr308 
Short-term DHA treatment induced a modest increase in phosphorylation of 
Thr308 of Akt which was present up to 1h (figure 5.3A).  After 6h, 
phosphorylation intensity had returned to its basal state.  Unlike with the Ser473 
residue, long-term treatment did not have any effect on the intensity of Thr308 
phosphorylation (figure 5.3B).  Although statistical significance could not be 
shown with three successive experiments, this trend was well established for 
short- and long-term DHA supplementation.   
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Figure 5.1 Effect of supplementation with different concentrations of 
docosahexaenoic acid (DHA) on NCM460 and CaCo2 cell proliferation.  
Cells were cultured in standard medium and supplemented with fatty 
acids (10 µM) in serum-poor medium for 48h.  The MTT assay was 
performed as described in the Methods section.  Values are expressed 
as percentages of controls (100%);  * p<0.001; # p<0.05 versus control. 
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Figure 5.2 A:  Effect of short-term (2’ – 6h) DHA supplementation on 
phosphorylation of Akt at Ser473 in CaCo2 cells.  B:  Effect of long-term 
(6h – 48h) DHA supplementation on phosphorylation of Akt at Ser473 in 
CaCo2 cells.  Graphs represent densitometric data of phosphorylated 
proteins; p>0.05 versus control. 
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5.2.3.  Phosphorylation of ERK1/2 and p38 MAPK 
With short-term DHA supplementation, a distinct trend was observed towards 
increased phosphorylation of ERK1/2 which decreased towards its basal 
intensity before 1h (figure 5.4A).  Long-term supplementation, however, yielded 
conflicting results in three successive experiments with regard to ERK1/2 
phosphorylation (figure 5.4B), and no meaningful conclusions could be made.  
Regarding the phosphorylation of p38 MAPK, short-term DHA supplementation 
did not seem to have any effect, although an increase was observed after 48h 
(figure 5.4A and B).  The total protein levels of ERK1/2 and p38 MAPK did not 
change. 
5.2.4.  Phosphorylation of p53 at Ser15 
Short-term DHA supplementation seemed to induce phosphorylation of p53 at 
Ser15, which was maximal at 10 – 15 minutes (figure 5.5A).  After 6h, 
phosphorylation intensity had returned to its normal state.  This trend was well 
established in three successive experiments, even though statistical 
significance could not be shown.  With long-term supplementation, increased 
phosphorylation was observed after 48h.  The total protein level of p53 did not 
change. 
5.2.5.  Cleavage of apoptotic proteins procaspase-3 and PARP 
Procaspase-3 can be cleaved by an initiator caspase into 20, 19, or 17 kDa 
active fragments (Uetsuki et al., 1999).  A monoclonal antibody which detects 
the 17 and 19 kDa subunits was used.  In normal conditions, equal amounts of 
these subunits were detected, which was taken to represent the basal level of 
apoptosis for CaCo2 cells.  Long-term DHA supplementation significantly 
altered the cleavage pattern of caspase-3 after 16h, when the level of the larger 
subunit decreased significantly (p<0.01), though this was not accompanied by 
an increase of the smaller subunit (figure 5.6).  Forty-eight hours following the 
addition of DHA, the 17 kDa subunit had nearly disappeared (p<0.01), 
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Figure 5.3 A:  Effect of short-term (2’ – 6h) DHA supplementation on 
phosphorylation of Akt at Thr308 in CaCo2 cells.  B:  Effect of long-term 
(6h – 48h) DHA supplementation on phosphorylation of Akt at Thr308 in 
CaCo2 cells.  Graphs represent densitometric data of phosphorylated 
proteins; p>0.05 versus control. 
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Figure 5.4 A:  Effect of short-term (2’ – 6h) DHA supplementation on 
phosphorylation of ERK and p38 MAPK (first and third row) in CaCo2 
cells.  B:  Effect of long-term (6h – 48h) DHA supplementation on 
phosphorylation of ERK and p38 MAPK (first and third row) in CaCo2 
cells; p>0.05 versus control. 
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Figure 5.5 A:  Effect of short-term (2’ – 6h) DHA supplementation on 
phosphorylation of p53 in CaCo2 cells.  B:  Effect of long-term (6h – 
48h) DHA supplementation on phosphorylation of p53 in CaCo2 cells.  
Graphs represent densitometric data of phosphorylated proteins; p>0.05 
versus control. 
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together with a return of the 19 kDa subunit to its normal intensity.  The 
disappearance of the smaller fragment of caspase-3 at 48h was coupled with 
the cleavage of PARP to yield an 89 kDa fragment.  This was detected with the 
use of a monoclonal antibody which detects uncleaved PARP (116 kDa) as well 
as its subunits following cleavage (89 and 24 kDa), although the smaller 
fragment could not be detected together with the larger one in these blots. 
 
 
Figure 5.6 The effect of long-term DHA supplementation on the cleavage of 
procaspase-3 and PARP in CaCo2 cells.  The graph represents 
densitometric data of caspase-3 subunits; * p<0.01 versus control. 
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CHAPTER 6 
RESULTS III 
 
In this chapter, the results presented were obtained from experiments 
investigating possible crosstalk between the components of the various 
signalling pathways shown to be modulated by DHA.  This was accomplished 
by using three pharmacological kinase inhibitors and also RNAi directed against 
p38 MAPK (figure 6.1).  The pharmacological inhibitors were wortmannin (an 
inhibitor of PI3 kinase), PD 98059 (an inhibitor of MEK), and SB 203580 (a p38 
MAPK inhibitor).   
 
 
Figure 6.1 The inhibition of signalling kinases by pharmacological inhibitors and 
short interfering RNAs.  Abbreviations:  ERK, extracellular regulated 
kinase; MEK, MAP/ERK kinase; MEKK, MEK kinase; PI3 kinase, 
phosphatidylinositol 3 kinase; siRNA, short interfering RNA. 
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6.1.  THE EFFECTS OF DIFFERENT KINASE 
INHIBITORS ON AKT, ERK, P38 AND P53 
PHOSPHORYLATION 
CaCo2 cells were cultured until 70-80% confluence and treated with the 
inhibitors (wortmannin, 500 nM; PD 98059, 10 μM; SB 203580, 10 μM) for 30 
min prior to 30 min DHA supplementation (10 μM) in serum-poor medium.  The 
phosphorylation status of Akt (Ser473 and Thr308), ERK (Thr202/Tyr204), p38 
(Thr180/Tyr182), and p53 (Ser15) was then measured with phospho-specific 
antibodies.  Changes in total protein level were also measured with antibodies 
that recognise the proteins of interest regardless of their phosphorylation status.  
In an MTT assay, the possibility of any vehicle effects (DMSO and ethanol) was 
ruled out (figure 6.2).   
 6.1.1.  Phosphorylation of Akt 
Treatment with wortmannin reduced the phosphorylation of Akt at Ser473, in 
both the presence and absence of DHA (figure 6.3).  Whereas PD 98059 and 
SB 203580 did not have any effect on Ser473 phosphorylation when given in 
the absence of DHA, DHA could not increase phosphorylation in the presence 
of PD 98059.  On the other hand, SB203580 did not have an inhibitory effect on 
the ability of DHA to increase Ser473 phosphorylation (p<0.05).  DHA 
supplementation increased Thr308 phosphorylation slightly (p>0.05), but not in 
the presence of inhibitors.  The inhibitors by themselves did not seem to have 
any effects on Thr308 phosphorylation. 
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Figure 6.2 The effects of ethanol (fatty acid vehicle) and DMSO (kinase inhibitor 
vehicle) on the functionality of CaCo2 cells; p>0.05. 
EtOH DMSO
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
Ar
bi
tr
ar
y 
un
its
 90
 
Figure 6.3 The effect of three kinase inhibitors on phosphorylation of Akt at Ser473 
and Thr308 with or without 30 min DHA supplementation.  CaCo2 cells 
were treated with either wortmannin (500 nM), PD98059 (10 μM), or 
SB203580 (10 μM) for 30 min.  Then, three groups were also treated 
with DHA (10 μM) for 30 min.  The graph represents densitometric data 
of phosphorylated proteins;  * p<0.05 versus control. 
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6.1.2.  The phosphorylation of ERK  
The MEK inhibitor, PD 98059, suppressed the phosphorylation of ERK1/2, in 
the presence and absence of DHA (figure 6.4).  Wortmannin also reduced 
ERK1/2 phosphorylation in both cases.  Although SB 203580 did not have an 
inhibitory effect in the absence of DHA, DHA seemed unable to increase 
ERK1/2 phosphorylation following SB 208350 treatment.  However, from short-
term experiments it can be concluded that ERK1/2 phosphorylation had already 
returned to a basal state by 30 minutes following DHA addition. 
6.1.3.  Phosphorylation of p38 MAPK 
The inhibitors did not seem to have any effect on p38 MAPK phosphorylation 
(figure 6.5).  DHA did not intensify or repress the effects of any inhibitors, and 
also failed to modify phosphorylation by itself.   
6.1.4.  Phosphorylation of p53 at Ser15 
In these experiments, 30 min DHA supplementation suppressed Ser15 
phosphorylation significantly (p<0.01), in contrast to the results from short-term 
supplementation experiments (figure 6.6).  This suppression was also seen in 
the presence of SB 203580 (p<0.05), although wortmannin and PD 98059 
attenuated this.    
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Figure 6.4 The effect of three kinase inhibitors on phosphorylation of ERK with or 
without 30 min DHA supplementation.  CaCo2 cells were treated with 
either wortmannin (500 nM), PD98059 (10 μM), or SB203580 (10 μM) 
for 30 min.  Then, three groups were also treated with DHA (10 μM) for 
30 min.  The graph represents densitometric data of the phosphorylated 
protein; p>0.05. 
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Figure 6.5 The effect of three kinase inhibitors on phosphorylation of p38 MAPK 
with or without 30 min DHA supplementation.  CaCo2 cells were treated 
with either wortmannin (500 nM), PD98059 (10 μM), or SB203580 (10 
μM) for 30 min.  Then, three groups were also treated with DHA (10 μM) 
for 30 min.  The graph represents densitometric data of the 
phosphorylated protein; p>0.05 versus control. 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
Ct
r
Wo
rtm
an
nin
PD
98
05
9
SB
20
35
80
W+
DH
A
PD
+D
HA
SB
+D
HA DH
A
%
 o
f c
on
tr
ol
- + - - + - - - Wortmannin 
- - + - - + - - PD 98059 
- - - + - - + - SB 203580 
- - - - + + + + DHA 
Phospho-p38 
Total p38 
 94
 
 
Figure 6.6 The effect of three kinase inhibitors on phosphorylation of p53 at Ser15 
with or without 30 min DHA supplementation.  CaCo2 cells were treated 
with either wortmannin (500 nM), PD98059 (10 μM), or SB203580 (10 
μM) for 30 min.  Then, three groups were also treated with DHA (10 μM) 
for 30 min.  The graph represents densitometric data of the 
phosphorylated protein;* p<0.05; # p<0.01 (n=2). 
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6.2.  RNAi AGAINST P38 MAPK  
RNA interference is a powerful tool to prevent the protein expression of a 
certain gene.  In this experiment, CaCo2 cells were transfected with siRNAs 
against p38 MAPK in standard medium for 24h.  Thereafter, cells were 
supplemented with DHA (10 μM) in serum-poor medium for 30 minutes prior to 
lysis and preparation for Western blotting. 
 
Samples treated with siRNA are in lanes 3 and 4 (figure 6.7).  These lanes 
show decreased band intensity when probed for total p38 MAPK.  
Phosphorylation of p53 at Ser15 was suppressed by DHA when p38 MAPK was 
knocked down, although the knockdown by itself did not affect phosphorylation.  
Phosphorylation of Akt at Ser473 was not suppressed by the knockdown of p38 
MAPK.    
 
 
Figure 6.7 The effect of siRNA directed against p38 MAPK on total p38 protein, 
and the phosphorylation of p53 at Ser15 and Akt at Ser473.  Lanes 1 
and 2 contain controls with 10% and 2% foetal calf serum, respectively.  
The total protein level of β-actin was used to control for equal sample 
loading. 
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CHAPTER 7 
DISCUSSION  
7.1.  THE EFFECTS OF FATTY ACIDS ON 
PROLIFERATION OF NORMAL AND CANCER 
CELLS 
In order for a therapeutic agent to be truly effective, it should be toxic to tumour 
cells without harming normal cells.  From the literature, it seems as though fatty 
acids fulfil this criterion.   Also, fatty acids have been shown to augment 
standard cancer therapeutics in two ways:  (1) by enhancing efficacy of 
chemotherapeutic drugs, and (2) by reducing the side effects associated with 
chemotherapy (Hardman, 2002).  
 
In the current study, both cell lines were representative of the colon, and a 
tissue-specific effect was thereby ruled out.  This is important, as many early in 
vitro studies are currently disregarded due to different origins of the cell lines 
(Diggle, 2002).  None of the fatty acids used in the current study were toxic to 
the normal cells, although they had differential effects on the cancer cells (figure 
3.1).  As many published studies have already shown the effectiveness of DHA 
on cancer cells, our results were not surprising and encouraged us to use DHA 
in the subsequent experiments.   
 
Our results have also shown that lower fatty acid concentrations are more 
appropriate, as normal cell proliferation is not compromised. A high dose, on the 
other hand, is cytotoxic to both normal and cancer cells (figure 4.1).  Even 
though many similar studies have been published over the years on the effect 
of fatty acids on cancer cells, in some of these the fatty acid concentrations that 
were used (Chen and Istfan, 2000) would have been cytotoxic to normal cells 
as well.  Therefore the appropriateness of those studies to encourage the 
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potential use of fatty acids in cancer therapy can now be questioned. 
7.2.  THE INCORPORATION OF FATTY ACIDS INTO 
MEMBRANE PHOSPHOLIPIDS 
It is known that the fatty acid composition of membrane phospholipids can 
influence the function of certain membrane proteins such as receptors, 
transporters, and enzymes (Spector and Yorek, 1985).  Such changes would 
also have downstream signalling effects, and could ultimately change the profile 
of gene expression.  It is also known that cancer cells tend to have a low 
content of PUFAs within membrane phospholipids and thus rigidity of cell 
membranes (Dianzani, 1989).  In the present study, the low content of PUFAs in 
cancer cells was confirmed (table 4.1).  Also, it was shown that a SFA such as 
PMA is extremely poorly incorporated in cell membranes, which is in 
accordance with previous studies in CaCo2 and also other cell lines (Nano et 
al., 2003).  MUFAs (such as OA in this study) were also poorly incorporated and 
revealed only 1.2-fold and 1.3-fold increases (versus control) in OA and 20:1 n-
9 content, respectively, together with a 1.4-fold decrease in 16:1 n-7. However, 
OA was found to be the most abundant fatty acid in the CaCo2 cells, followed 
by PMA.  Because the tumour cells are PUFA deficient, cells may synthesise 
OA from stearic acid (18:0) to compensate for this (Kinsella et al., 1990), 
thereby attempting to counteract membrane rigidity.  High OA content is also 
associated with the rapid growth and division of cancer cells (Ntambi, 1999).   
 
Supplementation with AA was able to decrease the OA content of the cells, and 
although this was not a major change, a longer treatment period could have 
lowered this further.  This is probably due to the displacement of OA by AA 
within the phospholipid, rather than the metabolism of OA in the presence of 
AA.  AA also increased the AA content of the phospholipids by 1.4-fold.  The 
elongated form of AA, 22:4 n-6, also increased 2.2-fold.  It has already been 
shown much earlier that AA supplementation results in a large increase in 22:4 
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n-6 in cells of endothelial origin (Spector and Yorek, 1985), and this was 
therefore to be expected.  It may also suggest that the additional AA was not 
employed for eicosanoid synthesis. Although 22:4 can be converted to 22:5 
(docosapentaenoic acid), this did not occur during this time of supplementation 
(48h), which could indicate a lowered Δ4 desaturase activity in the CaCo2 cells.   
 
DHA was also incorporated effectively, and did not have such complex effects 
on the CaCo2 membranes as AA or OA, as the content of no other fatty acids 
apart from DHA was altered (1.5-fold increase after 48h).  It is known that DHA 
is preferentially incorporated into the phosphatidylethanolamine (PE), 
phosphatidylserine (PS) and to a lesser extent phosphatidylcholine (PC) 
fractions of phospholipids, and preferentially accumulates in the inner leaflet of 
membranes (Stillwell and Wassall, 2003).   
 
Taken together our results confirm how effectively PUFAs are incorporated into 
phospholipids of membranes.  The enrichment of tumour cell membranes with 
PUFAs has important therapeutic potential, as it had been shown to enhance 
the cytotoxicity of therapeutic agents (Burns and Spector, 1987).  This could 
easily be ascribed to the fact that the increased membrane fluidity that 
accompanies PUFA enrichment, enhances the uptake of such agents and may 
also reverse resistance to certain therapeutics (Burns and North, 1986; Liu and 
Tan, 2000; Conklin, 2002).  Numerous reports have also ascribed increased 
membrane permeability and increased flip-flop rates to DHA enrichment 
(Stillwell and Wassall, 2003), which could also enhance the uptake of 
therapeutics. 
 
Many mechanisms have been proposed to explain the tumour suppressive 
effect of n-3 PUFAS.  It is likely that this phenomenon is mediated by a 
combination of these mechanisms, rather than the activity of a single 
mechanism.  Some of these mechanisms are as follows: 
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• If n-3 PUFAs are available, they will inhibit eicosanoid synthesis from 
AA, especially reducing the growth-promoting prostaglandin E2 which is 
often found in higher concentrations in tumour cells (Rose and Connolly, 
1999; Hardman, 2004). 
• The n-3 PUFAs can inhibit PKC, thereby suppressing mitosis and 
multiplication of tumour cells (McCarty, 1996).  PKC activation has been 
associated with the onset of colon cancer (Rose and Connolly, 1999).   
• The induction of COX-2 is associated with many cancers and is 
associated with maintaining tumour integrity, angiogenesis, and 
metastasis (Whelan and McEntee, 2004).  This can be suppressed by n-
3 PUFAs (Rose and Connolly, 1999). 
• The n-3 PUFAs may be peroxidised to generate free radicals that may 
be involved in the initiation of apoptosis and growth arrest (Larsson et 
al., 2004). 
• Some n-3 PUFAs, particularly DHA, when incorporated in phospholipid 
membranes, induce changes in the lateral organisation of membranes 
which may influence the location of signalling proteins and have 
downstream signalling effects (Wassall et al., 2004). 
7.3.  DHA MODULATES SIGNALLING MOLECULES 
DHA has been shown to modulate the activities of various signalling enzymes 
and transcription factors in various cell types.  These include ERK1/2 in human 
T lymphocytes (Denys et al., 2001), Akt in neurons (Akbar et al., 2005), p38 
MAPK in vascular smooth muscle (Diep et al., 2000), adenylyl cyclase in liver 
cells (Flier et al., 1985), nuclear factor (NF) κB in macrophages (Novak et al., 
2003), and Ras and PKC in colon cells (Holian and Nelson, 1992; Collett et al., 
2001).  However, these studies were not done in the context of cancer 
research.  An exception is PKC, which has been studied extensively in tumour 
cells and is believed to be involved in the beneficial effects of PUFAs (Holian 
and Nelson, 1992; Blobe et al., 1994).  
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7.3.3. Akt 
At this point in time, the mechanism of the activation of Akt is still controversial, 
even though it is a widely researched field.  It is clear that the sites required for 
activation are Ser473 and Thr308 (in Akt1), and it is mostly believed that 
phosphorylation occurs at Thr308 before phosphorylation at Ser473 takes place 
(Scheid and Woodgett, 2003).   
 
Our results have shown that following short-term DHA supplementation, an 
increase in phosphorylation occurs at both these residues and returns to a 
basal state within less than 6h (figures 5.2A and 5.3A).  Whether this transient 
heightened phosphorylation, which is indicative of activation, has any effects on 
gene expression is questionable.  However, long-term DHA supplementation 
has suppressed Ser473 phosphorylation, while Thr308 phosphorylation 
remained unaltered (figures 5.2B and 5.3B).  Very low Thr308 phosphorylation 
is considered to be normal in resting cells (Scheid and Woodgett, 2003) and it 
was thus not expected that DHA should suppress Thr308 phosphorylation as 
well.  However, the decreased Ser473 phosphorylation can be associated with 
decreased activity of Akt, as the phosphorylation of this residue is associated 
with full activation.   
 
Because interaction with membrane phospholipids is essential for Ser473 
phosphorylation (Scheid and Woodgett, 2003), the way in which DHA modifies 
phospholipids could be responsible for the decreased Ser473 phosphorylation 
observed.  Moreover, as Akt signalling is associated with cell survival (Datta et 
al., 1999), the restriction of full Akt activity could lead to apoptosis (Kennedy et 
al., 1997).   
 
Wortmannin, an irreversible inhibitor of PI3 kinase by means of covalent 
modification (Wymann et al., 1996), suppressed the phosphorylation of Akt at 
Ser473 and also inhibited the increased phosphorylation induced by DHA 
 101
(figure 6.2).  With the use of the MEK inhibitor (PD 98059) DHA was also 
unable to induce the heightened phosphorylation that was seen with the use of 
DHA (alone or following SB 203580 treatment).  This supports a possible 
upstream role for MEK or perhaps ERK1/2 in the phosphorylation of Akt at 
Ser473.     
 
Because PDK1 requires interaction with phosphoinositides (Dong and Liu, 
2005), it was not surprising to see that Thr308 phosphorylation was abolished 
by wortmannin.  Interestingly, DHA was also unable to induce phosphorylation 
at Thr308 following treatment with either PD 98059 or SB 203580.  This could 
suggest upstream signalling roles of MEK, ERK1/2, or p38 MAPK in the 
activation of PDK1, the kinase responsible for Thr308 phosphorylation.   
 
Although it has been suggested that p38 MAPK could be responsible for this 
phosphorylation following receptor stimulation by certain agonists (Dong and 
Liu, 2005), our results did not reflect this (figure 6.6).  The use of siRNAs to 
inhibit the expression of p38 MAPK did not diminish phosphorylation at the 
Ser473 residue, whether treatment with DHA followed or not. 
7.3.3. ERK1/2 
The increased phosphorylation of ERK1/2 observed with DHA supplementation 
(figure 5.4) could actually reflect activation of PKC, as it is known that PKC can 
activate the ERK MAPK cascade via Raf-1 (Kolch et al., 1993; Hausser et al., 
2001).  Numerous studies have shown that both EPA and DHA can actually 
reduce PKC activity (May et al., 1983; Holian and Nelson, 1992).  If this was the 
case, it may well have been reflected in ERK1/2 activity.  However, conflicting 
results were obtained regarding ERK phosphorylation in three successive 
experiments with long-term DHA supplementation, and whether DHA could 
suppress this crucial survival-associated pathway cannot be stated with 
certainty.   
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In the experiments with inhibitors it was found that PD 98059 successfully 
inhibited the phosphorylation of ERK1/2, in the presence and absence of DHA 
(figure 6.3).  Wortmannin also reduced ERK1/2 phosphorylation in both cases.  
Previous reports have stated that PI3 kinase is an upstream mediator of 
ERK1/2 activity (Fuller et al., 2001), which would explain this effect.  Although 
SB 203580 did not have an inhibitory effect in the absence of DHA, DHA 
seemed unable to increase ERK1/2 phosphorylation following SB 208350 
treatment.  However, the specificity of this inhibitor has recently been 
questioned (Godl et al., 2003).  Nonetheless, short-term experiments have 
shown that ERK1/2 phosphorylation had already returned to a basal state by 30 
minutes following DHA addition, which is a partial explanation for the lack of 
phosphorylation in those groups that were treated with an inhibitor and DHA. 
7.3.3. p38 MAPK 
Although fatty acids have been shown to induce rapid p38 MAPK 
phosphorylation in other systems (Diep et al., 2000), it was unable to do so in 
the CaCo2 cells (figure 5.4).  A change in phosphorylation following DHA 
supplementation was only observed at 48h.  This could be indicative of a 
delayed stress response, and might also contribute, together with suppression 
of Akt signalling, to apoptosis via ASK1 (Matsukawa et al., 2004).  It has been 
speculated repeatedly that the cytotoxicity of PUFAs in cancer cells can be 
ascribed to their peroxidation and the generation of free radicals (Sagar and 
Das, 1995; Conklin, 2002).  Oxidants are known to activate ASK1 upstream of 
p38 MAPK, and this pathway can be associated with apoptosis (Matsukawa et 
al., 2004).  It is possible that ASK1 is not activated by DHA supplementation 
directly, but instead by other apoptotic proteins such as Fas and TRAF2 
(Kyriakis and Avruch, 2001).  This could explain the delayed response that was 
observed in p38 MAPK activation following DHA supplementation and why no 
short-term effects were observed.   
 
The kinase inhibitors did not affect p38 MAPK phosphorylation (figure 5.4).  
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Also, the effects of the inhibitors were not intensified or repressed by DHA, 
which was to be expected since DHA failed to induce p38 MAPK 
phosphorylation by itself. 
7.3.4.  p53 (Ser15) 
Numerous residues at which p53 can be phosphorylated have been described.  
Similarly, p53 has been described as a substrate for many kinases in vitro.  
Nevertheless, relatively little is known concerning which sites are 
phosphorylated by which kinases (Ashcroft et al., 1999).  The current study has 
specifically examined phosphorylation at Ser15, which is primarily associated 
with DNA damage (Shieh et al., 1997).  This site is known to be phosphorylated 
by ATR and DNA-PK in vivo (Bulavin et al., 1999). 
 
Short-term DHA seemed to increase p53 (Ser15) phosphorylation transiently, 
as this effect has already been abolished in less than 6h (figure 5.5A).  
However, phosphorylation at Ser15 was strongly increased within 16h and 
remained elevated (figure 5.5B).  This increase can be associated with a stress 
response associated with loss of DNA integrity.  Once again, increased 
oxidative stress that could be associated with PUFA supplementation could be 
responsible for damage to DNA and Ser15 phosphorylation.   However, Ser15 
phosphorylation alone was found to be insufficient to block the interaction 
between p53 and its regulator, MDM2 (Dumaz and Meek, 1999).  Therefore, 
although it is possible, it cannot be stated with absolute certainty that p53 can 
mediate apoptosis following long-term DHA supplementation.   
 
In the kinase inhibitor experiments, Ser15 phosphorylation was lower with DHA 
than the control value after 30 minutes (figure 6.6).  This effect was also 
observed with SB 203580 and DHA treatment, whereas it was attenuated by 
both wortmannin and PD 98059.   
 
A possible role for p38 MAPK in the phosphorylation of p53 at Ser15 was 
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investigated with RNAi (figure 6.7).  It was shown that following knockdown of 
p38 MAPK, DHA is unable to induce phosphorylation of Ser15.  This implicates 
a role for p38 MAPK in the phosphorylation of p53 at Ser15 and also for p53 
activation. 
 7.3.5.  Caspase-3 and PARP 
Caspase-3 is an important effector caspase in the apoptotic pathway.  It is 
responsible for the cleavage of various substrates, including PARP, a DNA 
repair enzyme.  We have demonstrated that DHA significantly induced caspase-
3- and PARP cleavage in the CaCo2 cells (figure 5.6). However, differential 
cleavage of the inactive enzyme was apparent.  At 48h, the cleaved caspase-3 
subunit was 19 kDa in size, which was also when cleavage of PARP first 
became apparent.  Although it is known that caspase-3 can be cleaved at more 
than one site to yield active enzymes of different molecular masses (Uetsuki et 
al., 1999), our results implicate a possible differential role for these different 
active enzymes. Furthermore, it was also previously demonstrated in HT-29 
cells (also a colon cancer cell line) that a low dose of another long chain n-3 
PUFA, EPA, could induce caspase-3 activity after 24 and 48h of exposure 
(Latham et al., 2001).   
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CHAPTER 8 
CONCLUSION  
 
This was the first complete study, to our knowledge, to investigate the range of 
effects of fatty acids on different cellular processes such as proliferation, 
membrane composition, and signal transduction in the context of colorectal 
cancer.  Our results have clearly shown that DHA, the longest chain and most 
unsaturated fatty acid in biological systems (Stillwell and Wassall, 2003), has 
multiple cellular effects (figure 8.1).  These effects include changes in 
membrane properties, decreased proliferation of cancer cells whilst normal cells 
remain unaffected, and also, the modulation of different signalling molecules.  It 
is probable that the down regulation of survival-related signalling observed can 
be a direct consequence of the changes to membrane structure and that this 
would ultimately decrease the functionality of cancer cells. 
 
A schematic representation of the proposed mechanisms of the action of DHA 
on CaCo2 cells, based on the findings of the present study, is given in figure 
8.1.  Firstly, the incorporation of DHA into membrane phospholipids may result 
in increased overall membrane fluidity.  This could lead to changes in the lateral 
organisation of membranes, which in turn affects signalling proteins associated 
with the membranes, such as PKC and PDK1.  A possible down regulation of 
PKC activity due to membrane reorganisation, would lead to decreased signal 
transduction to ERK, a kinase associated with cell survival and proliferation.  
Thereby, the activity and downstream signalling of ERK is suppressed.  
Membrane reorganisation could also decrease the activity of the kinase 
responsible for Ser473 phosphorylation of Akt, another kinase central to cell 
survival and proliferation.  Thereby the full activation of Akt is suppressed.  
Thus, DHA is able to reduce proliferation of CaCo2 cells by the down regulation 
of survival-associated kinase activity.  We propose this as the primary anti-
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tumourigenic mechanism of DHA. 
 
Furthermore, we also propose a secondary anti-tumourigenic mechanism of 
DHA.  This mechanism involves the ability to up regulate the activity of proteins 
associated with apoptosis.  It is a secondary mechanism because it only 
becomes apparent more than 16h following DHA supplementation, whereas the 
primary mechanism is evident much earlier.  The secondary mechanism can 
possibly be ascribed to DHA peroxidation and the subsequent generation of 
free radicals.  Free radicals are able to activate both ASK1, a kinase upstream 
of p38 MAPK (which is associated with stress and apoptosis), and p53, a 
transcription factor that can also be connected to stress (especially DNA 
damage) and apoptosis.  It is proposed that p38 MAPK and p53 is involved in 
the induction of the apoptotic cascade, as the cleavage of the apoptotic 
proteins, procaspase-3 and PARP, was observed.   
 
From the use of pharmacological inhibitors and siRNA, we can also propose 
other novel findings.  Firstly, our results suggest a role for ERK in the activity of 
PDK1, the kinase responsible for Thr308 phosphorylation in Akt.  Secondly, we 
propose that p38 MAPK is responsible for the phosphorylation of Ser15 in p53.   
 
Our results confirmed the anti-tumourigenic efficacy of n-3 PUFAs in cancer 
cells, together with their safety with regard to normal cells.  However, why 
normal cells are not harmed, remains an open question.  Nevertheless, the 
clinical use of n-3 fatty acid therapy, whether as a precautionary agent or as an 
adjuvant to conventional therapy, is long overdue. 
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Figure 8.1 Proposed signalling mechanisms of DHA in CaCo2 cells.  Abbreviations:  
ASK1, apoptosis signal-regulating kinase 1; ERK, extracellular regulated 
kinase; MAPK, mitogen-activated protein kinase; MEK, MAP/ERK 
kinase; PARP, poly(ADP-ribose) polymerase; PDK1, phosphoinositide 
dependant kinase 1; PKC, protein kinase C; PUFA, polyunsaturated 
fatty acid. 
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